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One of the biggest challenges in antitumor therapy is to deliver chemotherapeutic drug 
directly to the desired location, at the lowest dose possible and thus to increase the effectiveness 
of treatment and decrease strong adverse effects of chemotherapy. Anticancer drugs, which are 
the pharmacological ground for approaches to antitumor therapy, usually exhibit high cytotoxic 
properties, however they are not specific in reaching the desired location in the body. This 
results in a systemic distribution of cytotoxic agents, which provoke well known strong side 
effects. Advances in nanotechnology offer new approaches for targeted delivery of anticancer 
agents, which may reduce or prevent side effects by targeting the drug molecules directly to the 
tumor region.  
Iron oxide nanoparticles (NPs) have drawn great interest in recent years because of their 
unique physical and chemical properties. Administration of functionalized magnetic iron oxide 
NPs became one of the strategies to improve safety and sensitivity to cancer chemotherapy, and 
these nanostructures are attractive materials that could be used in various bioapplications, 
including diagnostic imaging and targeted therapy.  
Magnetic NPs were synthesized by alkali co-precipitation of iron salts followed by 
coating with surface modification agent, poly(ethylene glycol)-block-poly(4-
vinylbenzylphosphonate) block copolymer (PEG-PIONs). An anticancer drug DOX, which 
clinical use is associated with severe cardiotoxicity, was loaded onto PEG-PIONs surface 
(PEG-PIONs/DOX), and to my knowledge, this formulation showed higher drug encapsulation 
efficiency than other formulations previously reported. PEG-PIONs/DOX were examined in 
terms of their physicochemical and magnetic properties using different methods. Synthesized 
NPs were stable in physiological mimicking conditions and had a hydrodynamic diameter 
appropriate for biomedical use. The present findings of characterization of magnetic properties 
demonstrated that synthesized nanosystem is promising tool for potential magnetic drug 
delivery. In vitro studies showed that PEG-PIONs/DOX exhibit stable and continuous in vitro 
drug release and antiproliferative effects on cancer cells. Fluorescent imaging indicated 
internalization of the PEG-PIONs/DOX in cancer cells. Moreover, in vivo biodistribution 
studies showed that PEG-PIONs/DOX preferentially accumulate in the tumor region via 
enhanced permeability and retention effect. In addition, analysis of the serum levels of enzymes 
indicated that PEG-PIONs/DOX reduced the cardiotoxicity associated with free DOX.  
The results presented in this dissertation suggest that PEG-PIONs/DOX have a potential 
for their future bioapplications and may lead to obtain tissue selective and/or externally guided 





Due to their unique physical and chemical properties, superparamagnetic iron oxide 
nanoparticles (SPIONs) have drawn a great interest in recent years. Administration of 
appropriately functionalized magnetic iron oxide nanoparticles (NPs) became one of the 
strategies to improve safety and sensitivity to cancer chemotherapy by targeting the drug 
molecules directly to the tumor region. These NPs are attractive materials that could be used in 
various bioapplications, including diagnostic imaging and targeted therapy. Although advances 
in nanotechnology offer new nanoparticle-assisted drug delivery systems, the therapeutic 
efficacy of these materials remains to be clarified. One of the major issues is low accumulation 
efficiency of NPs in the tumor region, also their stability and drug loading capacity have still 
some scope for improvement. To have the best possible control of quality of produced 
nanosystem, I decided to synthesize and characterize the material from the basic step – the 
biocompatible block copolymer PEG-derivative to functionalized SPIONs containing 
anticancer drug doxorubicin (DOX). The main aim of this work was to design and characterize 
a stable, biocompatible and injectable nanocarrier with antiproliferative effect on cancer cells 
and high drug loading efficiency and to explore their usefulness as a potential targeted drug 
delivery system.  
This dissertation is divided into 5 chapters. The Introduction reviews previous work and 
basic concepts of SPIONs, their most important properties and the possibility for their 
application in biomedicine. In particular, the methods of SPIONs synthesis and their surface 
modification, which is crucial for in vivo administration have been introduced and 
characterization of SPIONs for bioapplications has been presented. Next, magnetic properties 
of these materials and characterization of SPIONs as drug delivery systems are described. 
Finally, the enhanced permeability and retention effect is discussed in detail. 
The second chapter introduces the reader to the main experimental methods used in this 
work and it is subdivided into 6 subsections to facilitate reading and arrange all the techniques 
used. Materials used in my research are presented in first subsection. Then, synthesis of block 
copolymer is described. Next, synthesis and complete physicochemical characterization of 
functionalized magnetic NPs are discussed. The two last subsections of this chapter include 
their presentation of performed in vitro as well as in vivo experiments.  
The third chapter reports Results and discussion of this work; characterization of block 
copolymer is presented, the physicochemical properties of synthesized and appropriately 
functionalized NPs containing DOX are described: size, stability in physiological conditions, 
9 
 
drug loading efficiency; magnetic properties, their superparamagnetic and crystalline nature 
indicated that prepared NPs are promising tool for their potential bioapplication; in vitro studies 
demonstrated stable and continuous drug release profile, antiproliferative effects on cancer cells 
and internalization of NPs in cancer cells; in vivo biodistribution studies showed preferred 
accumulation in the tumor region via enhanced permeability and retention effect and reduction 
of the cardiotoxicity associated with free DOX.  
The fourth chapter comprises general conclusions, a short summary of the work 
performed and goals achieved. 





























Jednym z głównych założeń rozwoju i doskonalenia współczesnej terapii 
przeciwnowotworowej jest dostarczenie leku bezpośrednio do wybranej lokalizacji w 
organizmie, stosując jego możliwie jak najmniejszą dawkę oraz kontrolując jego uwalnianie. 
Osiągnięcie tego celu umożliwiłoby zmniejszenie toksyczności chemioterapii i wpłynęłoby 
korzystnie na efektywność leczenia. W literaturze znajdujemy wiele raportów naukowych o 
nowoczesnych systemach dostarczania leków, także tych, opartych na zastosowaniu różnych 
nanomateriałów, jednakże ich skuteczność jest ciągle dyskusyjna. W celu udoskonalenia ww. 
układów nanonauki zaproponowały nowe kierunki celowanych terapii. Jednym z nich są, 
będące tematyką mojej pracy doktorskiej, magnetyczne nanocząstki jako nośnik leku 
przeciwnowotworowego. Superparamagnetyczne nanocząstki tlenku żelaza (SPIONs) są dziś 
przedmiotem intensywnych badań ze względu na ich unikalne właściwości fizyczne i 
chemiczne. Dzięki możliwości stosowania licznych modyfikacji powierzchniowych (np. 
powlekanie nanocząstek biozgodnymi polimerami, dołączanie leków i innych biomolekuł) 
można manipulować ich własnościami i kontrolować ich parametry. Zabiegi takie korzystnie 
wpływają na biodegradowalność i biokompatybilność w ustroju, zmniejszają toksyczność oraz 
zwiększają stabilność wprowadzanych nanoukładów. Obecnie trwają intensywne prace 
badawcze nad potencjalnym zastosowaniem SPIONs w celowanej terapii 
przeciwnowotworowej i diagnostyce medycznej. Jednakże głównym problemem jest ich niska 
kumulacja w rejonie guza, a stabilność układów w warunkach odzwierciedlających naturalne 
oraz stopień enkapsulacji leku wciąż podlegają dyskusji. 
Głównym celem przeprowadzonych badań była synteza oraz kompleksowa 
charakterystyka fizykochemiczna i biologiczna magnetycznych SPIONs pokrytych 
oryginalnym, biokompatybilnym polimerem - pochodną polietylenoglikolu, zawierających lek 
przeciwnowotworowy - doksorubicynę (PEG-PIONs/DOX). Przeprowadzone przeze mnie 
badania miały na celu stworzenie biokompatybilnego układu do wstrzykiwania dożylnego, o 
wysokim stopniu enkaspulacji środka cytostatycznego i działaniu antyproliferacyjnym na 
komórki nowotworowe, mającego w przyszłości potencjalne zastosowanie w terapii celowanej 
leczenia nowotworów.  
PEG-PIONs/DOX otrzymano stosując metodę koprecypitacji soli żelazowych w 
środowisku zasadowym. Następnie, w wyniku funkcjonalizacji zsyntetyzowanym wcześniej 
biozgodnym polimerem blokowym, otrzymano hydrofilowy materiał, do którego powierzchni 
podłączono lek przeciwnowotworowy – doksorubicynę.  
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Zweryfikowano parametry fizykochemiczne, właściwości magnetyczne i biologiczne 
uzyskanych nanocząstek. Właściwości fizyczne otrzymanych układów scharakteryzowano 
metodami dynamicznego rozpraszania światła, spektroskopii UV-Vis oraz wysokorozdzielczej 
transmisyjnej mikroskopii elektronowej. Właściwości magnetyczne określono metodami 
elektronowego rezonansu paramagnetycznego, magnetometrii SQUID oraz dyfraktometrii 
promieni rentgenowskich. Przeprowadzono analizę cytotoksyczności układów za pomocą testu 
żywotności MTT na komórkach nowotworowych raka jelita grubego C-26 oraz zbadano 
biodystrubycję DOX z otrzymanych NPs w badaniu in vivo na mysim modelu zwierzęcym.  
Niniejsza praca podzielona jest na pięć rozdziałów. W pierwszym paragrafie 
zatytułowanym Introduction opisano wcześniejsze prace badawcze i podstawy dotyczące 
SPIONs, ich najważniejsze właściwości oraz możliwości ich potencjalnego zastosowania w 
biomedycynie. W szczególności przedstawiono różne metody syntezy SPIONs oraz dokładnie 
opisano stosowane do tej pory metody modyfikacji ich powierzchni, który to etap jest 
niezbędny dla ich administracji in vivo. Następnie szczegółowo sklasyfikowano cechy SPIONs 
jako układu do bioaplikacji, na które należy zwrócić uwagę przy ich projektowaniu, t.j. 
stabilność, średni rozkład wielkości, toksyczność oraz właściwości magnetyczne. 
Przedstawiono właściwości SPIONs jakie muszą spełniać jako nośniki leków w terapiach 
celowanych oraz szczegółowo opisano fizjologiczne zjawisko zwiększonej przepuszczalności 
naczyniowej i retencji zachodzące w guzie.  
Drugi rozdział, Experimental methods, opisuje krótką charakterystykę większości 
technik eksperymentalnych użytych do badań i został podzielony na sześć podrozdziałów w 
celu uporządkowania metodyki badań oraz ułatwienia czytania pracy. Materiały użyte w 
badaniach zostały wymienione w pierwszym podrozdziale. Następnie opisana została synteza 
polimeru blokowego, użytego w kolejnym etapie do opłaszczenia magnetycznych NPs. W 
dalszej części przedstawiona została synteza i kompletna charakterystyka fizykochemiczna 
sfunkcjonalizowanych PEG-PIONs/DOX. Ostatnie dwa podrozdziały zawierają prezentację 
wyników uzyskach z badań PEG-PIONs/DOX przy użyciu technik in vitro na komórkach 
nowotworowych oraz in vivo na mysim modelu zwierzęcym. 
W rozdziale trzecim zatytułowanym Results and discussion przedstawiono rezultaty 
wraz z dyskusją przeprowadzonych badań. W rozdziale tym opisuję charakterystykę 
zsyntetyzowanego polimeru blokowego. Następnie, uzyskane wyniki z pomiarów właściwości 
fizykochemicznych otrzymanych i odpowiednio sfunkcjonalizowanych magnetycznych NPs 
zawierających lek przeciwnowotworowy, średni rozkład wielkości, stabilność w warunkach 
odzwierciedlających fizjologiczne, stopień enkapsulacji substancji aktywnej; właściwości 
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magnetyczne PEG-PIONs/DOX, wykazanie superparamagnetyzmu oraz krystalicznej 
struktury. Badania in vitro przedstawiają stopniowy profil uwalniania DOX z NPs w kwaśnym 
pH odzwierciedlającym środowisko w rejonie tkanki nowotworowej, działanie 
antyproliferacyjne na komórki nowotworowe oraz internalizację NPs do komórek rakowych. 
Następnie zostały przedstawione wyniki z badań in vivo biodystrybucji leku w poszczególnych 
organach po podaniu PEG-PIONs/DOX i wolnego roztworu DOX oraz porównanie 
toksyczności in vivo wolnej DOX w porównaniu do układu PEG-PIONs/DOX. 
Rozdział czwarty, Conclusions, podsumowuje wyniki badań. Stwierdzono utworzenie 
stabilnych magnetycznych NPs w warunkach fizjologicznych, o odpowiednim do zastosowań 
biomedycznych profilu hydrodynamicznym, wąskim rozkładzie wielkości, o wysokim stopniu 
enkapsulacji leku i jego przedłużonym uwalnianiu z układu PEG-PIONs/DOX. Badania 
właściwości magnetycznych PEG-PIONs/DOX potwierdziły ich superparamagnetyczną naturę 
oraz strukturę krystalograficzną. Badania in vitro wykazały skuteczną internalizację przez 
komórki nowotworowe oraz efektywne zmniejszenie ich żywotności. Wychwyt DOX z PEG-
PIONs/DOX w tkance guza myszy był większy niż równoważne dawki wolnego roztworu 
DOX, a związana z zastosowaniem leku kardiotoksyczność była znacznie mniejsza w 
przypadku zastosowania układu PEG-PIONs/DOX. 



















Aim Of The Work 
 
The aim of this work was to design a stable, biocompatible and injectable nanocarrier 
with antiproliferative effect on cancer cells and high drug encapsulation efficiency. The general 
objective was to examine the physical and biological properties of synthesized 
superparamagnetic iron oxide nanoparticles (SPIONs) with anticancer agent. That allowed to 































1.1. Literature review of Superparamagnetic Iron Oxide Nanoparticles 
 
Over the past three decades, scientists and engineers have reached the possibility to measure 
and construct structures on the scale of atoms and molecules. Nanotechnology holds great 
opportunities to create materials with enhanced features and attributes by penetrating to the 
nanoscale – one billionth of a meter. Nanomaterials are already being used or tested in a wide 
range of products such as cosmetics, clothing, sport equipment, medical and electronic devices, 
among others. Nowadays, it is possible to synthesize, characterize and specifically modify the 
functional properties of nanostructures in variety of applications (Figure 1), including the 
biomedical use, for example as contrast agents for magnetic resonance imaging (MRI) 
[Schweiger et al.2011; Ling et al.2011; Rosen et al.2012; ] or for drug delivery in targeted 
therapy [Butoescu et al.2009; Arnold et al.2007; Y. Liu et al.2010]. Over 50 years ago, Freeman 
et al.[(Freeman, Arrott, and Watson 1960)] presented the pioneering concept of using an 
external magnetic field coupled with magnetic carriers. Since then, much research has been 
done in this field, leading to the design of various magnetic particles and vectors, to deliver 
drugs to required area in vivo [A. S. Lübbe et al.1996;  a S. Lübbe, Alexiou, and Bergemann 
2001]. Recently, the special interest is focused on superparamagnetic iron oxide nanoparticles 
(SPIONs). They show unique physical and chemical properties such as superparamagnetism, 
and can be delivered to the specific site through external magnets [Kodama 1999]. A particle 
of the magnetic material below a critical diameter (for maghemite γFe2O3 or magnetite Fe3O4 
of about 5 - 20 nm) (A. K. Gupta and Gupta 2005], contains only one single magnetic domain, 
thus it is at a state of uniform magnetization at any field without interaction with neighbour 
domains in a well dispersed material. An object consisting of many of these nanoscale particles 
displays magnetic properties under an applied external magnetic field, however magnetization 
would not remain after its removal [Harris et al.2003]. The reason for this phenomenon, called 
superparamagnetism, is that these domains will return to disordered status by having enough 
space to refuse the interaction between each other while there is no extra magnetic field applied. 
This feature is especially necessary in biomedical applications, because it enables to maintain 
colloidal stability of SPIONs and protects against potential clogging of the vessels and 
capillaries. The current research on SPIONs is opening up broad horizons for their use in the 
biomedical sciences. They have been used for both diagnostic as well as therapeutic purposes. 
The utility of SPIONs as MRI contrast agents has been studied for more than two decades, 
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allowing diagnosis of progressive diseases in their early stages [Weinstein et al.2010]. Via 
intravenous injection of the contrast agent, SPIONs are injected into a blood vessel and taken 
up by the solid cancer cell during circulation. This leads to clear images of soft tissue with 
magnetic agents. MRI may also play important role in thero-diagnostic purpose. In a recent 
preclinical study, specific tumoral accumulation of intravenously injected magnetic 
nanoparticles (NPs) labeled with a near-infrared dye and covalently linked to small interfering 
RNA (siRNA) was demonstrated by in vivo MRI and optical imaging; specific silencing of an 
apoptosis inhibitor protein was achieved, leading to increased tumor apoptosis 
and necrosis [Medarova et al.2007]. From a therapeutic point of view, targeting of cancer is the 
most pursued area, with emphasis on treatment using hyperthermia [Ling et al.2011] or delivery 
of chemotherapeutics to required site [Cao et al. 2009]. Tumor cells have shown a greater 
sensitivity to heat compared to healthy cells. This has led to the use of hyperthermic therapies 
in the clinic, often in combination with other treatments [Neuberger et al.2005]. Hyperthermia 
is a therapeutic procedure that promotes the increase of temperature in body tissues in order to 
change the functionality of the cellular structures. Temperature increase between 41°C and 
42°C can induce tumor cell death, as the tumor cells are less resistant to sudden increases in 
temperature than the normal surrounding . The  rise  in  temperature  changes the functioning 
of many enzymatic and structural proteins in cells, in turn altering cell growth and 
differentiation, which can induce apoptosis [Silva et al. 2011; Laurent and Mahmoudi 2011; ]. 
Advances in the area of nanotechnology have contributed to the development of 
superparamagnetic materials, which are well recognized as promising hyperthermia method for 
cancer treatment [Laurent and Mahmoudi 2011], however it is still limited by the fact that the 
anticipated heating distribution is difficult to control [Salloum, Ma, and Zhu 2008]. The main 
disadvantage of the majority of available chemotherapies is that they are comparatively non-
specific. The intravenous administration of the drugs gives rise to an overall distribution in the 
body, producing harmful side-effects due to the non-selectivity between tumor and healthy 
cells. Therefore, one of the biggest challenges is to deliver chemotherapeutic directly to the 
desired location, at the lowest dose possible and thus to increase the effectiveness of treatment 
and decrease strong adverse effects of chemotherapy. Using SPIONs as the new nanocarriers 
may provide a physical and chemical targeting method for drug delivery [Debrassi et al.2011; 
Maver et al.2009; Zou et al.2010; ]. Increasing importance of SPIONs applications have also 
been found in the areas of gene delivery [Prijic et al.2012; Cheong et al.2009], cell death with 






Figure 1. Bioapplications of SPIONs. 
 
1.1.1. Superparamagnetic Iron Oxide Nanoparticles synthesis  
 
It has been a great scientific and technological challenge to produce magnetic NPs that 
fulfil the requirements for biomedical applications. Iron oxides, both γFe2O3 or Fe3O4, occur 
naturally as nano-sized crystals in the earth’s crust generated by various environmental sources 
such as volcanoes and fires. SPIONs, either γFe2O3 or Fe3O4, can be generated as air pollution 
or industry, but for their bio-applications they are appropriately synthesized [Karlsson, 
Holgersson, and Möller 2008]. Existing primarily used methods are mainly physical and 
chemical routes of synthesis. The main aim in SPIONs fabrication is to control the reaction 
conditions in a way to enable synthesis of NPs with a narrow size distribution, high level of 
monodispersity and homogenous composition [Bulte et al.2001]. In order to maximally 
facilitate use of SPIONs in therapeutic applications, MRI or drug delivery, their high 
magnetization values are required. Hydrodynamic particle size is an important parameter that 
influences magnetization values as well as dissolution and stability [A. K. Gupta and Gupta 
2005]. Therefore, the reaction conditions during their synthesis should have the opportunity to 
be modulated, to generate particle size with large surface area, which in turn allows SPIONs to 






















Figure 2. Three different routes of SPIONs synthesis.  
 
 
Most of chemical methods allow to modulate conditions of the synthesis reaction in order to 
achieve SPIONs with desired physicochemical properties. The most remarkable advantage of 
chemical methods is that they have appreciable control of particle size, composition and particle 
shape [A. K. Gupta and Gupta 2005]. Physical methods are elaborated procedures that often 
suffer from the inability to control the size of particles in the nanometer range [C. S. Lee, Lee, 
& Westervelt, 2001; ]. Once the core of SPIONs has been synthesized, the appropriate surface 
modification with biocompatible molecules [Bulte et al.2001; A. K. Gupta and Curtis 2004; 
Catherine C. Berry et al.2003; ] should follow, which can either be performed in situ or via 
post-synthesis methods [Laurent et al.2008].  
One of the most popular procedures to fabricate SPIONs, that has been widely used during last 
years, is co-precipitation technique [A. K. Gupta and Gupta 2005]. Conventionally, in this 
method magnetite is prepared by the addition of base to an aqueous solution of Fe2+ and Fe3+ 
ions in a 1:2 stoichiometry, which produces a black precipitate of spherical magnetite NPs of 
uniform sizes. The overall reaction may be written as follows: 
 


















According to the thermodynamics of this reaction, a complete precipitation of magnetite can be 
expected between pH 9 and 14, while maintaining a molar ratio of Fe2+/Fe3+ is 1:2 [A. K. Gupta 
and Gupta 2005]. In order to prevent them from possible oxidation in air as well as from 
agglomeration, Fe3O4 produced by reaction presented above are usually coated with organic or 
inorganic molecules in situ. In this technique, the type of salts used (e.g. chlorides, sulphates, 
nitrates, etc.), Fe2+ and Fe3+ ratio, pH and ionic strength of the media determines size, shape 
and composition of generated NPs. SPIONs are crystalline structures that are governed by the 
principles of crystal formation and growth. Precipitation from a solution is a fundamental 
method of crystallization, which involves two processes, nucleation and growth, which are the 
principle pathways for the formation of solids. In general, for precipitation to occur, there must 
be a saturated medium, in which addition of any excess solute will cause precipitation and the 
formation of nanocrystals (Burda et al.2005]. Formation of tiny crystalline nuclei occurs when 
the solution is supersaturated [Jun, Lee, and Cheon 2007], leading to a short single burst of 
nucleation, followed by the decrease of concentration and stopping of nucleation. Then, the 
nuclei can grow uniformly by diffusion from the solution to their surfaces, until an equilibrium 
concentration is achieved [Lodhia et al.2010]. The main advantages of co-precipitation method 
are it is mild and simple synthesis procedure, typically carried out in aqueous media under 
ambient conditions and the amount of produced NPs per one batch is large. However, problems 
arise from the particle size distribution, which are strongly dependent on a large number of 
procedural parameters, including pH, the concentration and ratio of reactants, ionic strength 
and temperature of the reaction mixture. In an attempt to produce ideally controllable and 
reproducible particles, many research groups have experimented with a variety of these 
parameters to establish the best conditions for co-precipitation method [Valenzuela et al.2009; 
Iida et al.2007 ]. Taking into consideration all of the obtained assumptions, this route directly 
generates hydrophilic monodisperse SPIONs with narrow size distribution. Controlling the size 
of the particles in co-precipitation method is the key step to producing SPIONs with narrow 
size distribution.  
Due to that challenge, alternative synthesis techniques such as the microemulsion (water-in-oil) 
method were developed. In this technique, the aqueous phase is dispersed as microdroplets in 
a continuous hydrocarbon phase (oil) surrounded by a monolayer of surfactant molecules [ K. 
Gupta and Wells 2004]. Iron precursors in the form of soluble metal salt can precipitate as iron 
oxide in the water phase specifically located in the center of the micelles. Iron oxides do not 
precipitate in organic phase as the iron precursors are unreactive in this phase. The main 
advantage of utilizing of microemulsion system for NPs formation is that their size can be 
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controlled by modulating the size of the aqueous micellar core [D. Zhang et al.2008]. However 
the primary drawback is that the large-scale success of the microemulsion technique has been 
limited by low production yields compared to co-precipitation and thermal decomposition 
method [Z. L. Liu et al.2004; Y. Lee et al.2005]. Microemulsion synthesis may also prove 
problematic due to the complex purification steps required for in vivo application to remove 
surfactants that have adhered to the particles [Lu, Salabas, and Schüth 2007]. The surfactants 
are required during fabrication process for separating and controlling the growing SPIONs, 
however some thought must be devoted considering the toxicity and biocompatibility of these 
molecules for pharmaceutical applications.  
Highly monodispersed NPs can be also synthesized using the thermal decomposition of 
organometallic precursors. This process includes two techniques: liquid phase and gas phase. 
The first one involves high-temperature decomposition of a metal-surfactant complex such as 
iron-oleate [J. Park et al.2004], iron  pentacarbonyl [Fe(CO)5] or ferric acetylacetonate 
[Fe(acac)3] in the presence of an organic solvent and is similar to the microemulsion methods, 
with  surfactants to aid in the dispersion and prevent the aggregation of the oleophobic iron 
oxide particles [Amara et al.2009]. The thermal decomposition synthesis method produces 
monodisperse, highly crystalline and non-aggregated SPIONs [Yoffe et al.2013], however 
more elaborated equipment and chemicals have to be used in the process and production yield 
is quite low comparing to simple co-precipitation method. It also shares the difficulty of the 
microemulsion technique of fabricating hydrophobic SPIONs which must be further processed 
for applications requiring the NPs to be dispersed in water phase.  
A recent development in the synthesis of SPIONs is the use of sonochemical route 
[Vijayakumar et al.2000; Kumar et al.2001]. This method involves the application of powerful 
ultrasonic radiation that creates acoustic cavitations which provides localized heat with a 
temperature of about 5000 ºC. At high temperature, the rapid formation, growth of nuclei and 
the implosive collapse of bubbles takes place. This method is an inexpensive and non-toxic way 
to synthetize SPIONs and it enables preparation of monodisperse NPs of a variety of shapes. 
However, it is unlikely that it will be industrially relevant as it lacks large scale synthesis and 
requires both specialized equipment and high-energy input in the form of ultrasonic irradiation 
[Yoffe et al.2013].  
The hydrothermal method is typically performed at higher pressures and reaction temperatures, 
where iron precursors in aqueous medium can be heated. It produces naturally hydrophilic 
SPIONs due to the aqueous solvent and is a universal process that can be performed with a 
variety of starting reactants and their proportions and reaction conditions (temperatures, 
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pressure) and also can be easily scaled up. [Wu et al.2009; Yan et al.2009]. It allows to obtain 
a broad range of particle sizes, magnetic properties and magnetization values, by which to 
control the properties of the synthesized SPIONs, while NPs under simple, environmentally 
friendly conditions.  
The previous research on chemical fabrication of magnetic NPs accumulated 
knowledge, experience and understanding on SPIONs synthesis procedures. Taking into 
consideration all of the studies and different aspects of SPIONs synthesis mentioned above, the 
fabrication of these NPs with an expected size distribution and stability is no longer the biggest 
challenge for researchers. Each of the synthesis methods can be controllable in a way to obtain 
SPIONs with required parameters and properties. Nowadays, the crucial factor for in vivo 
bioapplications is to modify their surface in a way to achieve the aim of stealth of SPIONs in 
the bloodstream and target them to the required area in the body.  
 
1.1.2. Superparamagnetic Iron Oxide Nanoparticles surface modification  
 
A major limitation of nanoparticle-based biodevices for in vivo applications (including 
drug delivery and imaging) is their nonspecific biodistribution. In the absence of any surface 
coating, SPIONs have hydrophobic surfaces with a large surface area to volume ratio. When 
NPs are administered intravenously, they tend to agglomerate through van der Waals attractions 
[Talelli et al.2009], adsorb plasma proteins, and consequently, form large clusters. These 
aggregates are rapidly cleared from the bloodstream by macrophages, namely in the lungs, liver, 
and spleen (organs of the reticuloendothelial system (RES)) [Ujiie et al.2011], before reaching 
their target. Several studies have already revealed that the in vivo behavior of NPs depends 
greatly on their morphology and surface properties [Hseih, Huang, and Lue 2002]. Therefore, 
certain modifications are required for biomedical applications of SPIONs to stabilize them 
under physiological conditions [Sun et al.2010].  
Surface modifications of SPIONs can be achieved using different approaches and could be 
modified e.g. through the creation of few atomic layers of inorganic metallic (e.g. gold) or oxide 
surfaces (e.g. silica) suitable for further functionalization by the attachment of various bioactive 
molecules or using functional groups of polymers [Chomoucka et al.2010]. With proper surface 
coating, SPIONs can be dispersed into suitable solvents, forming homogenous suspensions, 
called ferrofluids. Such a suspension can interact with an external magnetic field and be 
positioned to a required site, facilitating MRI for medical diagnosis and magnetic field-assisted 
cancer therapy. A numerous efforts have been put to conjugate targeting and therapeutic agents 
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onto SPIONs surfaces. They include covalent linkage strategies (direct nanoparticle 
conjugation, click chemistry, covalent linker chemistry) and physical interactions (electrostatic, 
hydrophilic/hydrophobic, affinity interactions). The chemical properties and functional groups 
present on the SPIONs coating determine the choice of conjugate method to be used. The main 
aim is to bind the targeting and therapeutic agents without compromising its functionality once 
attached. Functionality in such assemblies is dictated by the nature of the ligand and the manner 
in which it is attached. For example, if an antibody is bonded to the NP such that its recognition 
site is shielded, it may lose its ability to bind a target. A diverse range of materials have been 
used for coating including both inorganic and polymeric materials. Metallic core shell types of 
iron oxide NPs have been investigated by several researchers. These NPs have inner iron oxide 
core with an outer metallic shell of inorganic materials e.g. gold [M. Chen et al.2003; Carpenter 
2001], silica [Tartaj and Gonzµlez-carreæo 2001] or gadolinium [Morawski et al.2004]. These 
coatings give not only the stability to the NPs in solution, but also provides a good surface for 
subsequent functionalization with chemical or biological agents for various biomedical 
applications (Lin et al.2001]. Polymeric materials can be divided into natural and synthetic. 
Natural polymers includes coatings like dextran [Dutz et al.2007], chitosan [Unsoy et al.2012] 
or gelatin [Gaihre et al.2009 ], among others. Polymers based on poly(ethyleneglycol) (PEG) 
[Mojica Pisciotti et al.2014], poly(lactic-co-glycolic acid) (PLGA) [Wassel et al.2007; Zhao, 
Saatchi, and Häfeli 2009] or poly(vinyl alcohol) (PVA) [Petri-Fink et al.2005 ] are typical 
synthetic nanocoatings and offer a high potential in several areas of applications. PEG and PEG-
containing copolymers have been widely investigated for bio-applications [Nagasaki 2008; 
Yoshitomi, Miyamoto, and Nagasaki 2009]. PEG is a hydrophilic, uncharged and non-
immunogenic polymer [Allard-Vannier et al.2012] commonly used in commercial  products. It 
can be grafted onto NPs surface to form a hydrophilic outer layer that reduces protein adsorption 
as well as minimizes potential aggregation between particles. A very high requirement of 
coating density is desirable for the effective suppression of nonspecific interactions between 
NPs with biological components. Once the PEG density increases, the space between each 
polymer and its degree of freedom is reduced. The formation of the polymer molecule is then 
switched from a “mushroom” to a “brush” configuration (Figure 3). In the first one, the surface 
of the particle is still accessible, in the second one, the density and length of the polymer force 
the PEG-chains to be closely and regularly aligned, which reduces access to the NPs surface 
and in consequence reduces opsonization. NPs in the “mushroom” configuration are exposed 
to increased uptake by RES and those with “brush” configuration remain in the blood for 





Figure 3. Different polymer conformations on a polymeric nanoparticle, (a) represents the 
‘mushroom’ configuration, (b) represents the ‘brush’ configuration [Pirollo and Chang 2008]. 
 
 
Ujiie et al.[Ujiie et al.2011], highly improved PEG-chain density (PEG derivative with “brush” 
configuration) and obtained its high surface immobilization density, as well as its binding 
stability to the NPs surface, so that the PEGylated NPs remained intact in harsh biological 
environments over a long period. Most of NPs injected in vivo have some sort of coating that 
serves to avoid premature clearance, render the NPs water-soluble, protect particle surface from 
oxidation and improves biocompatibility. However, coatings can also provide chemical 
entrance points for conjugation of imaging, targeting and other functional modalities. Various 
biological molecules such as antibodies, proteins, targeting ligands, etc., may be bound to the 
polymer surfaces onto the NPs by chemically coupling via amide or ester bonds to make the 
particles target specific. The possibilities of targeting protein coatings are numerous. Targeting 
ligand such as transferrin is widely applied in the active targeting of anticancer agents, proteins 
and genes to primary proliferating cells via transferrin receptors                                                    
[Catherine C Berry et al.2004 ]. Folic acid preferentially targets cancer cells, is poorly 
immunogenic and folate receptor facilitates internalization of NPs [Y. Zhang, Kohler, and 
Zhang 2002]. There is another important role of surfactants on SPIONs. When SPIONs are 
injected as MRI contrast agent, they must locate the targeting area accurately and rapidly. 
Appropriate surfactant or functional attachment of surfactant could achieve such objective. 
Some experiments in vitro already approved folate-mediated NPs composed of PEG/poly ε-
caprolactone have potential of tumor cell-selective targeting [Gee et al.2003]. Optimization of 
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coating procedure for SPIONs biomedical use raises demands for nano-engineers. It allows 
dispersal into solvents to form ferrofluids, which can interact with an external magnetic field.  
The nature of the coating, charge state, and functionalization determine particle 
biocompatibility, stability, biodistribution, opsonization, metabolism, and clearance in vivo. 
Important advantages of prolonged circulation of drug carriers and drugs themselves in the 
bloodstream include the possibility of maintaining a required concentration of an active drug 
or drug carrier in the blood for a long time after a single administration; the ability to utilize the 
EPR effect for the accumulation of drugs in the areas with leaky vasculature and the possibility 
of enhancing ligand-mediated targeting of drug carriers into the areas with a limited blood 
supply, where an extended time is required to allow for a sufficient quantity of a drug in the 
target zone. 
 
1.1.3. Characteristics of Superparamagnetic Iron Oxide Nanoparticles for in vivo 
applications 
 
Systemic application of SPIONs, proves more difficult due to their rapid clearance from 
the blood by the RES and therefore, reducing the concentration of SPIONs reaching the target 
organ. To improve the systemic application of SPIONs, coating and functionalization with a 
targeting moiety is advantageous. SPIONs designed for biomedical applications are required to 
form a non-toxic aqueous dispersions with a narrow size distribution [Patel et al.2008], good 
colloidal stability under physiological conditions and prolonged circulation in the bloodstream. 
SPIONs for in vivo administration should be biodegradable and biocompatible. In order to 
improve the blood circulation behavior as well as the in vivo distribution of NPs, their sizes 
have to be controlled within the range 10–50 nm. Furthermore, NPs surface should be 
engineered to maximally reduce the nonspecific interactions with plasma proteins, since the 
RES-mediated rapid clearance of NPs is triggered by the adsorption of these proteins on their 
surface. 
 
1.1.3.1. Colloidal stability 
 
The dispersion stability of SPIONs under physiological conditions is crucial for their 
systemic administration. SPIONs are generally well tolerated in vivo, however appropriate 
surface modification or core-ligand composition play major role in physiological responses 
[Viali et al.2013]. In general, the stability of SPIONs is controlled by three types of interactions: 
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hydrophobic–hydrophilic, magnetic and van der Waals. NPs aggregate in suspension due to van 
der Waals forces in order to minimize the total surface or interfacial energy. Consequently, such 
aggregation impedes the efficacy of SPIONs in drug delivery (less drug loading) due to their 
low surface area and larger sizes. For that reason, the SPIONs surface is modified or coated 
with biocompatible functional molecules or polymers, which improves their colloidal stability 
in physiological media, reduces toxicity and significantly increases the blood circulation 
lifetime by minimizing the protein absorption onto NP surface. The ideal molecules used for 
stabilization of SPIONs should be biocompatible and biodegradable and surface modification 
can be carried out during synthesis or in a post-synthesis process.  
 
1.1.3.2. Size and size distribution  
 
The size distribution of SPIONs is the first parameter describing the quality of SPIONs 
related to their biological applications. The hydrodynamic diameter of NPs in hydrophilic 
ferrofluid after surface coating plays the vital role at in vivo application. Biomedical 
applications of SPIONs, including drug delivery, MRI, hyperthermia, and magnetic cell 
separation, depend on the magnetic properties of these particles, which in turn are largely 
dependent upon size. Only small enough NPs would display superparamagnetism and be stable 
in suspension with suitable surfactant coating. The magnetic properties of SPIONs are size 
dependent. The saturation magnetization and their sizes are linearly correlated as the surface 
curvature changes with size [Varanda et al.2002]. The smaller the particles, the longer their 
circulation time in blood vessel. Gupta et al.[A. K. Gupta and Gupta 2005] reported that the 
sizes between 10 and 100 nm are most effective for drug delivery purposes because they can 
evade the RES. They should remain in the circulation after injection and be capable of passing 
through the capillary systems of organs and tissues avoiding vessel embolism. In addition, it 
has been reported that particles which exceed 200 nm, tend to eliminate immediately by one of 
the organs from monoclear phagocytic system regardless of being polymer coated or not. 
Similarly, the small hydrodynamic size is important for achieving EPR effect and can make it 
tumor-specific accumulation feasible. Another main advantage of using particles of sizes 
smaller than 100 nm is their higher effective surface areas (easier attachment of ligands), lower 
sedimentation rates (i.e. high stability in suspension) and improved tissular diffusion. However, 
SPIONs with a particle size smaller than 2 nm may not be suitable for medical use[Wahajuddin 
2012]. This is due to the increased potential of particles in this size range to diffuse through cell 
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membranes, damaging  intracellular organelles and thus exhibiting potentially toxic effects. 




The nanoscale properties of NPs facilitate their novel bio-applications, however at the 
same time they can induce cytotoxicity by impairing major components of the cell 
(mitochondria, DNA and nucleus) [Brunner et al.2006; Nel et al.2006]. It can lead to significant 
toxic effects such as inflammation, generation of reactive oxygen species or chromosome 
condensation [Veranth et al.2007; Stroh et al.2004]. Since applications of SPIONs involve in 
vivo use, it is a vital factor to study their toxicity in appropriate model. Acute side effects should 
be avoided by testing in vitro cytotoxicity of NPs before injection. Uncoated SPIONs have very 
low solubility that can lead to precipitation after intravenous administration. Due to that fact 
their surface is appropriately modified, nevertheless the stability of these coatings and the 
consequences of their breakdown in vitro or in vivo have not been yet completely evaluated. 
Many of the clinically approved MRI contrast agents such as Ferridex, Resovist or Supravist, 
nowadays commercially available, are coated with dextran and its derivatives [Wang, Hussain, 
and Krestin 2001]. Numerous studies have reported that these NPs are biocompatible and lack 
cytotoxicity [Singh et al.2010]. Although, the results of recent studies indicates that these 
coatings are not strongly bound to the NPs surface and therefore there is a potential risk of 
detachment leading to aggregation and precipitation [McCarthy and Weissleder 2008], there is 
still insufficient information on the effect of these coatings on cytotoxicity associated with DNA 
damage and oxidative stress. The cytotoxicity of SPIONs coated with different polymers, with 
different shapes and morphologies has been comprehensively examined by Mahmoudi  research 
group [M Mahmoudi et al.2009; Morteza Mahmoudi, Shokrgozar, et al.2009]. According to 
their results, SPIONs showed no or little toxicity. In vivo tests [Weissleder et al.1989] on 
animals showed that even with a large dosage of 3000 µmol Fe of the iron based NPs per kg 
body weight, the histology and serologic blood tests have indicated that no side effects occurred 
after 7 days treatment. It has to be considered that in view of the in vivo applications, SPIONs 
suspension requires hydrophilic solvents such as physiological saline and be controlled at near 
neutral pH value about 7.4. Another in vivo investigations performed in humans found that a 
dextran-coated SPIONs - Ferumoxtran-10 - only induced mild and short in duration side effects 
such as urticaria, diarrhea and nausea [Anzai et al.2003 ]. It was concluded that they can be 
degraded and cleared from the bloodstream by the endogenous iron metabolic pathways. Iron 
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released from SPIONs is metabolized in the liver and then used in the formation of red blood 
cells or removed through renal clearance [Anzai et al.2003]. Use of SPIONs is increasing not 
only because their superparamagnetic properties, but also because their use is associated with 
low toxicity in human body [Karlsson et al.2009; Jeng and Swanson 2006].  
Understanding the potential risks associated with exposure to SPIONs and the influence 
of their coatings is crucial for their in vivo applications and every novel product for in vivo 
applications should be examined carefully. It is crucial to design functionalized SPIONs that 
can not only be sufficiently and effectively internalized, but also have appropriate saturation 
magnetization without compromising on cellular toxicity. Improved understanding of 
biological impacts will lead to fabrication of more biodegradable and biocompatible 
nanostructures that are well fit for their function [Singh et al.2010].  
 
1.1.3.4. Surface charge and protein adsorption 
 
When the drug-loaded NPs are injected systemically into the bloodstream, the size, 
morphology and surface charge are the three important parameters for their behavior. In 
general, particles with the same electronic charged surface are more stable in dispersion due to 
the homo-charged surface [Neuberger et al.2005]. The zeta potential can be qualitatively 
evaluated in NPs suspension in the presence of an electrolyte at a certain pH, as an electrical 
potential in the interfacial double layer on the surface of NPs. Surface charge of SPIONs can 
affect their cellular interaction, especially during endocytosis and phagocytosis [Coey and 
Wiesendanger 1993]. It was previously reported that polystyrene microparticles with a primary 
amine at the surface determined higher phagocytosis as compared to microparticles having 
sulfate, hydroxyl, phosphorous or carboxyl groups. Thus, it was found that for positively 
charged NPs in vivo phagocytosis the non-specific internalization process occurs faster as 
compared to neutral or negatively charged formulations. NPs carrying a positively charged 
surface are also expected to have a high nonspecific internalization rate and short blood 
circulation half-life. In conclusion, it was established that NPs are better to be neutral or slightly 
negatively charged on surface to have a reduced plasma protein adsorption and low rate of 
nonspecific cellular uptake [Link et al.2015].  
When NPs are administered into bloodstream, they are rapidly bound by plasma 
components including plasma proteins (opsonins). They can be easily adsorbed on the surface 
of NPs depending on their sizes, surface charge and morphology. Prolonging the circulation 
time in blood vessels is examining the capability of protein adsorption of the coating. Resistance 
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to their non-specific adsorption could prevent magnetic NPs from attachment of opsonin 
proteins and recognition by phagocytic cells in a certain time [Owens and Peppas 2006]. 
However, for the active targeting purpose, specific protein adsorption in the particle surface is 
allowed for functionalization of the NPs [Torchilin 2000]. Moghimi et al.[Moghimi, Hunter, 
and Murray 2001] performed an extensive research of the opsonisation process based on the 
NPs’ surface charge, size and hydrophilicity/hydrophobicity. The results of this study showed 
that the smaller the size and the higher the hydrophilicity of the NPs, the less efficient the 
opsonisation process is. In this context, PEG and folic acid coating have been found to be 
efficient for inhibiting the protein adsorption in vivo[Y. Zhang, Kohler, and Zhang 2002].  
With the requirements mentioned above, protein adsorption capability of the particles need 
to be under control that is not only resisting to the non-specific protein adsorption, but also 
adsorbing the specific functional proteins for targeting.  
 
1.1.4. Magnetic properties of iron oxide NPs 
 
Magnetic properties of iron oxide NPs are determined by a variety of factors including their 
composition, microstructure, size and shape, therefore their optimization is very important 
factor. The size and crystal structure of magnetic NPs determine their unique properties which 
make them useful as e.g. MR contrast agents or drug delivery systems. Materials like iron 
possess valence orbitals with unpaired electrons, thus exhibit paramagnetic properties. In 
general, magnetic materials are divided by several groups, i.e. diamagnetic, paramagnetic, 
ferromagnetic, ferrimagnetic and antiferromagnetic. The characteristic feature of diamagnetic 
materials (e.g. water, DNA, gold) is that their magnetic moments tend to align opposite to the 
external magnetic field (B0) and in consequence are repelled by the applied magnetic field. The 
opposite situation occurs in case of paramagnetic materials (e.g. gadolinium), which are 
























Figure 4. Alignment of individual magnetic magnetic moments in para- and diamagnetic 
materials. 
 
Materials, which characteristic feature is the creation of magnetic domains by absorbing and 
storing the (magnetic) energy, remain magnetic even after removal of B0 and are defined as 




     Ferromagnetism    Antiferromagnetism     Ferrimagnetism 
 
Figure 5. Alignment of individual magnetic moments within different types of materials. 
 
Ferromagnetics (e.g. iron, cobalt) contain only magnetic moments with the same value, going 
in the same direction. On the other side, ferrimagnetics (magnetite, maghemite) include two 
types of atoms with magnetic moments of different strengths that are arranged in an antiparallel 
arrangement [Teja and Koh 2009]. If the antiparallel magnetic moments are of the same 
magnitude, then the crystal is antiferromagnetic (hematite, chromium) and possesses no net 
magnetic moment. Another important type of magnetic behavior is superparamagnetism. It 
occurs in materials with specific size, shape and chemical composition. These parameters allow 
to obtain a single domain ferri- or ferromagnetic system with paramagnetic behavior possessing 
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a large magnetic moment. To evaluate their magnetic properties, the magnetization (M) vs. the 
external magnetic field alteration (H) characteristic can be performed (Figure 6). One of the 
parameters that can be obtained from these measurement is so called coercivity, i.e. the energy 
which is required to demagnetize material to its initial stage.  It is commonly known that 
coercivity of magnetic materials alters with their size. The variation of coercivity with NPs size 
is presented in Figure 6a. A single magnetic domain material has zero coercivity and is said to 
be superparamagnetic, but just until a particular size, then the coercivity increases as the particle 
size increases, and becomes a single- or multidomain ferri- or ferromagnetic system. The 
hysteresis loop differs for extremely small SPIONs (or single paramagnetic ions), SPIONs and 
ferromagnetic NPs (Figure 6b, 6c, 6d). Due to very a small magnetic moment, extremely small 
SPIONs exhibit almost a linear relationship between magnetization and magnetic field, and the 
saturation magnetization appears at very high magnetic field (Figure 6b). SPIONs do not exhibit 
coercivity due to fluctuations of magnetic moments (Figure 6c) and ferromagnetic NPs exhibit 
coercivity (Figure 6d).   
 
 
Figure 6. The magnetization (M) vs. the external magnetic field alteration (H) in different types 
of NPs [N. Lee and Hyeon 2012].  
 
One of the methods which allow to examine the properties of the NPs, especially 
paramagnetic materials is Electron Paramagnetic Resonance (EPR). EPR is a spectroscopic 
technique that allows the direct and non-invasive detection of paramagnetic species consisting 
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of one or more unpaired electrons in complex and non-transparent samples [Kempe, Metz, and 
Mäder 2010]. This method enables to examine short living, stable free radicals or transition 
metal ions, such as Mn2+, Fe3+ or Cu2+. Electron paramagnetic resonance (EPR) of the 
ferromagnetic particles, also known as FMR, is performed like any other EPR experiment, 
except that the samples contain approximately spherical aggregates of ferro or ferrimagnetic 
monodomains of the order of a few nanometers [Gamarra et al. 2009]. EPR is a technique based 
on the absorption of electromagnetic radiation, which is usually in the microwave frequency 
region, by a paramagnetic sample placed in an external magnetic field. The absorption takes 
place only for definite frequencies and magnetic field combinations, depending on the sample 
characteristics. EPR is based on interaction of the external magnetic field with magnetic 
moments of unpaired electrons in a sample, which leads to the splitting of the electron energy 





Figure 7. Energy levels for an electron spin (MS = ±1/2) in an applied magnetic field B0.     
 
Every electron has a magnetic moment and a single unpaired electron has only two allowed 
energy states. In the presence of an external magnetic field B0 , the electron's magnetic moment 
aligns itself either parallel Ms = -½ (then it has a state of lower energy) or antiparallel                  
Ms =  +½ (higher energy state) to the B0 field. An EPR signal is observed when the quantum of 
the electromagnetic wave energy hν is equal to the energy difference between the neighboring 
energy levels [Kabacińska et al.2012], which is described by the resonance condition: 
 




where g is the spectroscopic splitting factor and gives information about the kind of 
paramagnetic center, μB is the Bohr magneton and B0 is the induction of external magnetic field 
[Kempe, Metz, and Mäder 2010]. An unpaired electron can move between the two energy levels 
by either absorbing or emitting a photon of energy hv, such that the resonance condition, hv = 
∆E, is obeyed. EPR spectrometers measure the absorption of electromagnetic radiation. In a 
conventional X-band EPR experiments, the microwave frequency is chosen in the X-band, i.e. 
around 9.5 GHz. This frequency is kept fixed while the absorption of microwaves is monitored 
as a function of the varying external magnetic field. When the resonance condition is fulfilled, 
absorption of microwaves will be detected [Van Doorslaer et al. 2009] and a simple absorption 
spectra will appear (Figure 7). However, in EPR spectrometers, a phase-sensitive detector is 
used, which converts the normal absorption signal to its first derivative. This results in the 
absorption signal being presented as its first derivative in the spectrum (Figure 7). Therefore, 
the absorption maximum corresponds to the point where the spectrum passes through zero. This 
is the point that is used to determine the center of the signal. In order to fully evaluate the 
magnetic properties of examined SPIONs by EPR, the typical spectroscopic parameters: 
resonance magnetic field (Hr), g-spectroscopic splitting factor value, peak-to-peak line width 
(ΔHpp) are determined for collected spectra. These parameters are characteristics for particular 
types of magnetic nanomaterials and can provide number of important information regarding 
examined sample, like e.g. superparamagnetic properties. In order to understand the 
superparamagnetic features exhibited by the SPIONs under investigation, the temperature 
dependence of the parameters such as Hr and the individual ΔH are examined. And so, at 
elevated temperatures a superparamagnetic narrowing of the resonance spectra occurs, quoted 
as the superparamagnetic resonance (SPR). Temperature dependence of the individual ΔHpp is 
another cause of the temperature dependence of the SPR spectra, the broadening and shift to 
lower magnetic fields of the magnetic resonance spectra with the decrease of temperature is 
typical of superparamagnetic nanoparticles and has been recently observed in a number of 
systems [Berger Bissey, Kliava, and Estourn 2001]. The g-factor is characteristic of the local 
environment around the electron and the value depends on the orientation of the molecule with 
respect to the magnetic field [Van Doorslaer et al. 2009]. In order to examine the magnetic 
ordering of SPIONs, sample is cooled in the presence of the external magnetic field (field 
cooling, FC) the spin moments of NPs are then oriented approximately in parallel to the external 
magnetic field. The sample shows non-zero magnetization even if the field decreases to zero 
after freezing the sample. When the sample is cooled at a zero field (ZFC) the spin moments of 
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different domains are totally disordered and the sample shows zero magnetization when the 
field is zero [Dobosz et al.2014]. 
 
1.2. Superparamagnetic Iron Oxide Nanoparticles as drug delivery systems  
 
Drug delivery in cancer treatment has developed over the last several decades to become 
more accurate and efficacious. A few notable achievements in that field include: special pills 
coatings, which have resulted in formulations of sustained release of the drug substance (e.g. 
Lynparza® - Olaparib capsules, the first monotherapy for patients with deleterious or suspected 
deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer); development of 
drug patches (e.g. Sancuso® - Granisetron Transdermal System,  indicated for the prevention of 
nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy) 
with extended release of active ingredient that can penetrate through the skin to reach the 
bloodstream or development of nanoparticulate carriers to entrap and deliver anticancer drugs 
to disease locations (e.g. Doxil®, a liposomal carrier of doxorubicin hydrochloride). 
Nevertheless, even with the present achievements, more breakthroughs are still requested to 
further improve the efficacy of existing drugs, thus anticancer therapy. To reach these aims, it 
is important to understand the goals for drug delivery. For the purposes of its improvement, the 
goals are all similar and include: 1) protecting drugs from degradation during formulation or 
dosage preparation and after administration into the bloodstream; 2) controllable release period 
to achieve required concentration in the specific site for prolonged period of time or increased 
dosing intervals; 3) enhanced targeting of drug molecules to disease sites; 4) reducing overall 
adverse effects.  
Two major issues related to present cancer treatments are suboptimal efficacy and toxicity. 
No drug is free from side effects, and these ones usually arise from nonspecific drug action. In 
the case of anticancer therapy, adverse effects, such as bone marrow depression or reduced 
immunity, can be so severe that may lead to termination of therapy. In targeted drug delivery, 
the drug is released only within a targeted area of the body. Therefore the therapeutic effect in 
diseased cells and/or tissues is maximized while side effects of normal tissues are minimized. 
Furthermore, because of their large surface area and diverse surface chemistry, NPs can distinct 
drugs simultaneously to a diseased tissue. Targeting ligands can also be conjugated to the NPs 




SPIONs hold a great promise as carriers for site-specific drug delivery [Mody et al.2013]. 
In these nanosystems, the drugs are bound to the NPs surface (especially for NPs) or entrapped 
in magnetic liposomes and nano/microspheres. SPIONs-assisted drug delivery systems have 
been engineered to deliver peptides, DNA molecules, chemotherapeutic, radioactive and 
hyperthermic drugs [Leader, Baca, and Golan 2008; Antosova et al.2009; Scherer 2002]. The 
combination of appropriately modified SPIONs surface (e.g. with targeting ligand/ molecules 
attached to their surfaces) together with application of the external magnetic field is surface 
engineered SPIONs is nowadays considered as a desirable technology to target active substance 
from carrier to the required location where the drug is slowly released. Such a system has the 
potential to minimize the side effects and the needed dosage of the drugs [Rudge et al.2001; 
Neuberger et al.2005;  a S. Lübbe, Alexiou, and Bergemann 2001]. As mentioned previously 
there are few important considerations for SPIONs in drug delivery applications. The surface 
engineered magnetic iron oxide NPs are required to have superparamagnetic properties together 
with a specific size, which should be suitable for their delivery and a very narrow size 
distribution in order to have uniform biophysicochemical properties. The charge and surface 
chemistry are particularly crucial and strongly affect both the blood circulation time as well as 
bioavailability of the particles within the body. In addition, the magnetic properties are strongly 
related to impurity content or structural imperfections of the particles.  
The primary requirement of NPs for drug delivery is that the therapeutic molecules should be 
loaded in such a manner that its functionality is not compromised. Furthermore, these drug-
loaded NPs should release the active substance  at the desired rate and desirable location. Drug  
loading can be achieved either by conjugating the active substance on the surface or by co-
encapsulating drug molecules along with magnetic particles within the coating material 
envelope [Wahajuddin 2012]. Conjugation  of  therapeutic  agents  or  targeting  ligands  on  
the surface of NPs can be grouped under two categories, i.e. by means of physical interactions 
or conjugation by means of cleavable covalent linkages. In the first strategy, physical 
interactions such as electrostatic interactions or hydrophobic/hydrophilic interactions, can lead 
to coupling  of  the therapeutic agents or targeting molecules on the surfaces of SPIONs. For 
example, SPIONs coated with polyethylenimine, a cationic polymer, interact electrostatically 
with negatively charged DNA, demonstrating their applicability as transfection agents [Steitz 
et al.2007]. Similarly, dextran-coated SPIONs functionalized with negatively charged 
functional groups can couple with peptide oligomers via electrostatic interactions [Hildebrandt 
et al.2007]. Because of hydrophobic interactions, lipophilic drugs can easily be attached to 
SPIONs covered with hydrophobic polymers, from where the drug can be released when the 
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coating degrades. The second strategy involves linkage of the active substance directly with 
e.g. amino or hydroxyl functional groups present on the surface of polymer-coated SPIONs. 
This methods leads to enhanced loading capacity, but also results in more specific linkages, 
protecting the drug’s functionality and thus efficacy. Low entrapment efficiency is one of the 
major drawbacks of delivering the drug by conjugating the drug onto the surface coating the 
surface, because only a limited amount of drug can be conjugated in this way. Other 
disadvantages include highly stable linkages as a result of covalent bonding between drug 
molecules and the surface of SPIONs, leading to failure to release the drug molecule at the 
target site. Once SPIONs accumulate inside the required tissue, they should be able to release 
their drug payload at an optimal rate. However, in most cases upon injection into the in vivo 
environment the burst effect is observed, thus a majority of the drug substance is quickly 
released. As a consequence, inadequate amounts of the active substance reach the desired 
location. In order to reduce the burst effect, many research groups tried to modify SPIONs 
surface and so, Mahmoudi et al.[Morteza Mahmoudi, Simchi, et al.2009] synthesized SPIONs 
with a crosslinked poly (ethylene glycol)-co-fumarate coating. To evaluate the effectiveness of 
the coating, tamoxifen (i.e. an anti-oestrogen drug used to treat breast cancer) was loaded onto 
the surface of coated NPs. The results confirmed that the cross-linked polymer coating reduced 
the burst release by 21% in comparison with the non-cross-linked tamoxifen loaded particles. 
In another studies [Guo et al.2009; Hałupka-Bryl et al.2014], the surface of monodisperse 
SPIONs were appropriately modified to obtain required DOX release from NPs surface. The 
DOX release studies indicated that these SPIONs had a high drug loading capacity and 
favorable release kinetics for this drug.  
There is an increasing amount of new SPIONs formulations for targeted drug delivery 
nowadays. However, there is still lack of their biodistribution studies in in vivo experiments on 
animal models, moreover available studies show that still more than 95% of the NPs, are 
distributed to entire body in a non-specific manner after systemic administration [Hałupka-Bryl 
et al.2014], therefore less than 5% of administered NPs can reach the tumor site [Mok and 
Zhang 2013]. Thus recently, the main goal is not only to minimize toxicity of these 
nanosystems, but to significantly increase their bioavailability. It is also worth noting that the 
magnetic drug delivery systems follow similar rules as other pharmaceutical drug delivery 
strategies. More particularly, SPIONs magnetically brought to the required location, should 
release chemotherapeutic in order to extinguish the tumor, but should also undergo the same 
firm rules with respect to sterility, non-immunogenicity, and non-toxicity as any other 
developing drug delivery systems. 
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1.3. Enhanced permeability and retention effect 
 
The critical factor for application of NPs in biomedicine, such as diagnostic imaging and 
targeted therapies is their specifity for selected tissues [Misra 2008; Leuschner et al.2006]. In 
order to limit nonspecific cell binding, which may place healthy tissue at risk, NPs have been 
appropriately engineered to have an affinity for targeting tissues through passive, active, and 
magnetic targeting approaches. Passive targeting uses the predetermined properties of NPs to 
specifically locate in a given tissue region. Such selective targeting is not possible with low-
molecular-weight substances (many of the drugs being used today for chemotherapy), because 
small molecules do not distinguish tumor tissue from normal tissue. Therefore, common 
pharmaceutical agents reach most normal tissues and organs as well as tumor tissues by free 
diffusion-dependent equilibrium. Clearance of macromolecules from the interstitial space of 
normal and inflammatory tissues follows rapidly and steadily via the lymphatic system, even in 
the inflammatory state after extravasation from blood vessels. However, unlike in normal 
tissues, clearance of macromolecules from tumor is so impaired that they stay in the tumor 
interstitium for a long time [Hiroshi Maeda 1991]. This phenomenon has been characterized 
and termed the tumor-selective enhanced permeability and retention (EPR) effect [H. Maeda 
2001]. The EPR effect permits macromolecules, such as SPIONs, in the bloodstream to enter 
tumors more easily than healthy tissues. This phenomenon is primarily due to a combination of 
the fenestrated endothelium (vascular permeability) and the inefficient lymphatic drainage of 
the tumor, which generates the retention effect. The EPR effect is based on the principle that 
tumor cells, in order to grow rapidly, highly stimulate production of new blood vessels (rapid 
angiogenesis) that are poorly developed, thus the vasculature of tumor is leaky and damaged 
[Brannon-Peppas and Blanchette 2012; H Maeda et al.2000]. This process enables 
extravasation of NPs and other small macromolecules out of the vascular bed and accumulation 
in the tumor's interstitial space [R.K. Jain 2001]. Small molecules (less than 40 kDa) are rapidly 
cleared by diffusion, and large molecules and NPs (up to 500 nm size) are retained in the 
interstitial space due to the absence of drainage, leading to selective accumulation for a 
prolonged period of time of these agents resulting in increased contrast between the tumor and 
the surrounding healthy tissue [Thorek et al. 2006; Mcneil 2005]. In other words, high 
permeability of the tumor vasculature permits macromolecules and NPs to enter the tumor 
interstitial space, while the lymphatic filtration allows them to stay there. Unlike 
macromolecules, low-molecular-weight substances are not retained in tumors because of their 
ability to return to the circulation by diffusion [Hiroshi Maeda, Sawa, and Konno 2001]. EPR-
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mediated drug delivery is currently seen as an effective way to bring drugs to and into tumors, 
especially macromolecular drugs and drug-loaded pharmaceutical nanocarriers. Clearly, EPR-
based type of tumor targeting can function only if the macromolecules or NPs remains available 
in the bloodstream long enough, in order to provide a sufficient level of accumulation in the 
target. According to the EPR concept, biocompatible macromolecules accumulate at much 
higher concentrations in tumor tissues than in normal tissues or organs, even higher than those 
in plasma. Studies performed with a rat gliosarcoma model showed that cancerous tissues had 
a 10-fold higher uptake of dextran-coated SPIONs compared to healthy brain tissues [Moore et 
al. 2000]. As mentioned above, the most usual way to keep drug carriers in the blood long 
enough is to “mask” them by modifying their surface e.g. with certain water-soluble polymers 
such as  PEG [Klibanov et al.1990]. Previous research shows that it takes at least 6 hours for 
drugs in circulation to exert the EPR effect [H. Maeda 2001]. This means that any candidate 
pharmaceutical agent must have a molecular size above the renal clearance threshold, to 
circulate for a prolonged time. Also, polymeric drugs should not be cationic but either neutral 
or anionic, because the luminal surface of blood vessels is highly negatively charged and thus 
cationic polymer drugs are adsorbed on the vascular surface and are expected to have a short in 
vivo half-life. If a transported drug presents good cell permeability, a NPs that will release its 
content in the tumor interstitium is required. With the EPR effect, the intratumoral 
concentration of a drug is increased 10–100-fold compared with what is obtained when the drug 
is given conventionally. Moreover, the slow release of active substances from a carrier results 
in sustained, high intratumoral drug levels and lower plasma concentrations [Dosio et al.2011]. 
In this case, a biodegradable stealth nanoparticle is preferred that will accumulate by the EPR 
















All chemicals were used without further purification. Iron (II) chloride tetrahydrate (99.9%), 
acetic acid (99.0%), dimethyl sulfoxide, sodium chloride, sodium acetate, and Dulbecco’s 
phosphate-buffered saline (PBS) were purchased from WAKO (Wako Pure Chemical 
Industries, Ltd., Osaka, Japan). Iron (III) chloride hexahydrate and ammonia solution were 
obtained from Kanto Chemicals (Tokyo, Japan). Doxorubicin hydrochloride (>99.9%, MW 
579.98) was received from LC Laboratories (Woburn, MA, USA) and acetonitrile (99.99%) 
was provided by Honeywell (Muskegon, MI, USA). Dialysis membranes (MWCO 12-14 KDa) 
were purchased from SPECTRUMLABS (Ritto, Japan). Amicon Ultra centrifugal devices 
(MWCO 10 KDa) were obtained from Millipore, Toyonaka, Japan. PEG-b-PVBP was 
synthesized using the two-step side-chain conversion of the PEG-poly(4-chloromethylstyrene) 
block copolymer. To synthesize this polymer the following reagents were used: α-Methoxy-ω-
mercapto-poly(ethylene glycol) (MeOPEG-SH, Mn =5000 g mol
-1) was purchased from NOF 
Corporation (Tokyo, Japan), 4-Chloromethylstyrene (CMS) was provided by Seimi Chemical 
Co. Ltd., (Kanagawa, Japan), 2,2’-Azobisisobutyronitrile (AIBN; Kanto Chemicals Co. Ltd., 
Tokyo, Japan) was purified by recrystallization from methanol. Tetrahydrofuran (THF; Kanto 
Chemicals) was passed through purification columns (Glass Contour Solvent Dispensing 
System, HANSEN & Co., Ltd.) before use. Diethyl phosphite, diethyl 2-
bromoethylphosphonate, trimethylsilyl bromide (TMSBr) were purchased from Tokyo 
Chemical Industry, Co., Ltd, Japan, sodium hydride (NaH; 55% oil dispersion), sodium iodide 
(NaI), benzene and dichloromethane from Kanto Chemicals. Dialysis membranes (MWCO 3,5 
KDa) were purchased from SPECTRUMLABS (Ritto, Japan). In cell culture and iv vivo 
experiments were used as follows: penicillin, streptomycin, and neomycin (PSN), fetal bovine 
serum (FBS), trypsin-EDTA, and trypan blue stain (from Gibco, USA). Hoechst 33258 solution 
was obtained from Dojindo (Kumamoto, Japan) and cell proliferation Kit I (MTT) from Roche 
(Tokyo, Japan). Dulbecco’s modified Eagle’s medium (DMEM) was received from Sigma, 
USA. Murine colon adenocarcinoma 26 (C26) cells were provided by RIKEN BioResource 
Centre. Male BALB/c mice (age, 5-6 weeks and weight, 20-24 g) were purchased from Charles 




2.2. Synthesis of Poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) block 
copolymer 
 
PEG-b-PVBP  was  synthesized  by  the  two-step  side-chain  conversion  of  the  PEG-





Figure 8. Scheme of PEG-b-PVBP synthesis [(Kamimura et al.2011)]. 
 
At first, PEG-b-PCMS was synthesized by the radical telomerization of CMS using PEG-SH 
as a telogen [Yoshitomi, Miyamoto, and Nagasaki 2009]. Briefly, PEG-SH (1.0 g, 0.2 mmol), 
CMS (1.38 g, 10.0 mmol) and AIBN (16.5 mg, 0.1 mmol) were weighed into flask and 
dissolved in 10 mL of toluene. The obtained solution was then degassed through three freeze–
thaw–evacuate cycles. Polymerization was conducted for 24 h at 60ºC under the nitrogen 
atmosphere. Subsequently, the received polymer was purified by repeating precipitation into n-
hexane and diethyl ether and freeze-dried with benzene to obtain PEG-b-PCMS. The side chains 
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of the PCMS segment were converted to diethylphosphonate (PEG-b-poly(diethyl-4 
vinylbenzylphosphonate) (PEG-b-PDEVBP)) by the following reaction [(Boutevin et 
al.2002)]. NaH (126 mg, 5.25 mmol) and NaI (ca.40 mg) were weighted into a flask and 
dissolved in THF (5 mL). After cooling to 0ºC with magnetic stirring, diethyl phosphite (0.35 
mL, 3eq., 2.63 mmol) was added over 5 min, and the reaction mixture was further stirred for 
20 min. A solution of PEG-b-PCMS (500 mg) in 5 mL of THF was slowly added to the mixture 
at 0ºC, and the mixture was heated to room temperature and stirred for 12 h. Afterward, the 
solvent was removed by evaporation and the polymer was purified by dialysis (Spectra/Por 6, 
MWCO 3,500, SPECTRUM) for 2 days against excess methanol (2 L), which was changed 
after 3, 6, 9, 18, and 32 h. The final solution was concentrated under reduced pressure, followed 
by freeze-drying with benzene. The diethyl phosphonate moiety of the obtained PEG-b-
PDEVBP was hydrolyzed to the corresponding by treatment with TMSBr followed by 
methanolic hydrolysis. In brief, 450 mg of PEG-b-PDEVBP was weighted into a flask, solution 
of TMSBr (0.46 mL, 5eq., 3.55 mmol) in dichloromethane (5 mL) was added and the solution 
was mixed for 2 h at 45ºC. After the solvent was evaporated, 20 mL of methanol was added, 
and the mixture was stirred at room temperature for 15 h. After stirring, the solvent was 
removed by evaporation. The obtained polymer was purified by dialysis (Spectra/Por 6, MWCO 
3,500, SPECTRUM) for 2 days against excess methanol (2 L), which was changed after 3, 6, 
9, 18, and 32 h. The final product was concentrated under reduced pressure, followed by freeze-
drying with benzene to obtain PEG-b-PVBP. 
 
2.3. Synthesis of PEG-PIONs/DOX 
 
PEG-PIONs/DOX were prepared by optimized co-precipitation method. The initial iron 
oxide NPs precipitated upon addition of ammonium hydroxide to an aqueous mixture of iron 
(II) and iron (III) chlorides containing PEG-b-PVBP solution. Briefly, FeCl2 ·4H2O and FeCl3 
·6H2O in the ratio of 1:2 were weighted into a flask and dissolved in MilliQ water. PEG-b-
PVBP solution was added to this solution in the feed-weight ratio between polymer and iron 
salts 1:1 and the resulting mixture was vigorously stirred for 3 minutes. NH4OH (28% (v/v) in 
water) was added to this solution in ultrasonic bath. After the addition of ammonia, the 
dispersion was immediately put on vortex to vigorously stir for 3 minutes and then, the reaction 
mixture was allowed to stir at 1300 rpm at room temperature for 3 hours. Afterwards, the 
obtained mixture was dialyzed (MWCO 20,000) against 2L of water. The dialysate water was 
changed after 3, 6 and 15h.  
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The water-soluble anticancer drug DOX was chosen as a model drug after dialysis. The DOX 
loading was carried out by adding water-soluble drug substance (at final DOX concentration of 
1mg/ 1 mL PEG-PIONs suspension) to 7.2 mg of PEG-PIONs in 1 mL aqueous dispersion 
(based on magnetic NPs dry weight), mixed and ultrasonicated for 2 minutes. The reaction 
mixture was shaken on a rotary shaker at 1300 rpm in the dark at room temperature for 20 hours 
to facilitate DOX uptake. To optimize PEG-PIONs/DOX preparation, the unbound DOX was 
removed at fixed time intervals by ultrafiltration using an Amicon Ultra centrifugal devices 
(MWCO 10 KDa) pretreated with DOX. Then, the optical density of residual DOX in the 
supernatant was measured at 481 nm by using an ultraviolet-visible (UV-Vis) 
spectrophotometer (VarioSkan Flash plate reader; Thermo Fisher Scientific Inc., UK). After the 
measurement, the PEG-PIONs/DOX were redispersed for further DOX adsorption. Beyond a 
certain adsorption time, there were no further changes in the concentration of DOX since the 
loading capacity of the particles had reached saturation. The drug encapsulation efficiency (EE, 
refers to the percentage of drug encapsulated into the PEG-PIONs/DOX relating to the total 
drug added) and drug loading capacity (LC), refers to the drug content in the PEG-PIONs/DOX) 
of the NPs were calculated according to the following formulae: 
 
EE (%) = (WD – WS)/WD × 100%  
LC (%) = (WD-WS)/WPPD ×  100% 
 
where, WD refers to the weight of DOX added initially to system, WS refers to the DOX content 
in the supernatant, and WPPD refers to the weight of PEG-PIONs/DOX. 
The resulting PEG-PIONs/DOX were then dispersed in an appropriate medium and were stored 
at 4 °C before use [Kamimura et al.2012; Kayal and Ramanujan 2010]. The proposed objective 







Figure 9. Synthesis of PEG-PIONs/DOX. 
 
2.4. Physicochemical characterization of PEG-PIONs/DOX 
 
2.4.1. Particle size and morphology determination 
 
The morphology and core size of PEG-PIONs/DOX were observed by High-Resolution 
Transmission Electron Microscope (HRTEM) with a Jeol model ARM 200F operating at 
200kV. For sample preparation, a drop of PEG-PIONs/DOX aqueous dilute dispersion was 
deposited on cooper grid covered with a formal-carbon membrane.  
 
2.4.2. Stability studies 
 
The hydrodynamic size of the particles were measured by using Dynamic Light 
Scattering (DLS) technique with ZetaSizer Nano ZS (Malvern Instruments, Ltd., UK). Samples 
were prepared by dispersing PEG-PIONs/DOX in physiological saline, Phosphate Buffered 
Saline (PBS) and in PBS containing 10% Fetal Bovine Serum (FBS) and were stored over a 
period more than one moth at room temperature. Each measurement was performed at room 
temperature in triplicates. 
 
2.4.3. Study of complex formation (gel filtration chromatography) 
 
The gel filtration chromatography using PD-10 test column was used to confirm the 
complex formation between synthesized PEG-PIONs and DOX. For sample preparation, PEG-
PIONs/DOX suspension (1 mg DOX/1 mL PEG-PIONs) and free DOX solution (1 mg/mL) 
were loaded onto the top of a PD-10 column (Sephadex G25 medium; GE healthcare) and 
passed through a filtration column pre-rinsed with MilliQ water and PBS pH 7.5. Afterward, 
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the column was eluted with PBS pH 7.5 and fractions (0.5 mL/fraction) were retrieved. 32 
obtained fractions were collected and analyzed using UV-Vis spectroscopy (481 nm). Each 
measurement was performed in triplicates. 
 
2.4.4. Superconducting quantum interference experiments 
 
A superconducting quantum interference device (SQUID) was used to study the specific 
magnetic properties of synthesized PEG-PIONs/DOX. The field dependence of magnetization 
was recorded at room temperature in powder form. The magnetic field range in the 
magnetometer is ±7T and, sensitivity <6· 10-7 emu.  
 
2.4.5. Analysis of crystalline structure  
 
The crystalline structure of PEG-PIONs/DOX was studied by an X-ray diffraction 
(XRD) technique on Empyrean (PANalytical) diffractometer operated with Cu Kα radiation 
(1.54 Å), reflection-transmission spinner (sample stage) and PIXcel 3D detector, operating in 
the Bragg–Brentano geometry. The 2 Theta scans were recorded at room temperature (300 K) 
in angles ranging from 20 to 80 (°2Theta) with a step size of 0.003 (°2Th.) and continuous scan 
mode. The identification of PEG-PIONs/DOX was carried out by comparing the diffraction 
pattern of the sample with library data in powder diffraction files using ICDD PDF- 4+ 2012 
database. 
 
2.4.6. Electron paramagnetic resonance analysis 
 
The Electron Paramagnetic Resonance (EPR) measurements were carried out to study 
the magnetic properties of synthetized NPs using a conventional X-band Bruker EMX –10 
spectrometer with a magnetic field second modulation frequency of 100 kHz. Low temperatures 
were maintained by a Bruker temperature controller ER 4131VT. EPR analysis was carried out 
in the range of 77K – 290 K in a magnetic field sweep width of 6500 G. The typical 
spectroscopic parameters such as resonance field (Hr), g-spectroscopic splitting factor value, 
peak-to-peak line width (ΔH) were determined for all collected spectra.  
In order to examine the magnetic ordering of PEG-PIONs/DOX, sample of synthesized NPs 
was left for 5 minutes in the external magnetic field of 5000 Gs and then cooled to 120 K. When 
the sample is cooled in the presence of magnetic field (field cooling, FC) the spin moments of 
NPs are oriented approximately in parallel to the external magnetic field. The sample shows 
non-zero magnetization even if the field decreases to zero after freezing the sample. When the 
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sample is cooled at a zero field (ZFC) the spin moments of different domains are totally 
disordered and the sample shows zero magnetization when the field is zero [Dobosz et al.2014]. 
 
2.5. In vitro studies 
 
2.5.1. DOX release profile 
 
DOX release experiments were performed at least in triplicate using dialysis method 
(membrane MWCO 12-14 KDa). Analysis of DOX released from PEG-PIONs/DOX was 
performed in acetate buffer saline (ABS; pH, 5.7 and NaCl, 145 mM) and PBS (pH, 7.4 and 
NaCl, 145 mM) placed in an orbital shaker bath which was maintained at 37 °C in dark, and 
shaken horizontally at 120 rpm. At the particular range of time intervals (from 0.5 h to 96 h), 
200 μL of a sample of dialysate solution was withdrawn and replaced with an equal volume of 
fresh buffer. The DOX concentration was determined in dialysate samples from the intensity of 
the drug fluorescence at 481 nm by using VarioSkan Flash plate reader (Thermo Fisher 
Scientific Inc) using a calibration curve. The amount of DOX released from PEG-PIONs was 
expressed as a percentage of total DOX and plotted as a function of time. The solution obtained 
from a dialysis test performed using unloaded PEG-PIONs was used as a control.  
 
2.5.2. Cell culture and in vitro cytotoxicity assay 
 
C-26 colon cancer cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% FBS and 1% penicillin- streptomycin at 37 °C in a 
humidified 5% CO2 atmosphere. The medium was replenished every other day and the cells 
were collected by trypsinization using 0.25% of Trypsin-EDTA solution followed to subculture.  
The cytotoxic effect of DOX on C-26 cells was evaluated by a standard MTT assay as described 
in the literature [Munnier et al.2010]. MTT analysis is a non-radioactive, colorimetric assay 
[Morteza Mahmoudi et al.2010] frequently used to determine the antiproliferative effect on 
cells. The assay is based on the conversion of the yellow tetrazolium salt MTT to purple 
formazan crystals by metabolic active cells (Figure 10). The formazan crystals formed are 
solubilized and the resulting colored solution is quantified using a scanning multiwell 
spectrophotometer. The reduction takes place only when reductase enzymes are active, 
therefore the conversion is often used as a measure of cell viability.  
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Briefly, 2500 cells were seeded in each well of a flat-bottomed 96-well culture plate and 
allowed to grow for 24 h before desired treatment. Afterward, the cells were treated with series 
of suspensions of PEG-PIONs/DOX or free DOX at various concentrations and incubated for 
24 and 72 h. The culture medium without any drug formulations, only with PBS, were 
performed as a control. Then, the cells were incubated with MTT (5µL/ well) for 2-3 h at 37 °C 
in the dark. Subsequently, the resulting formazan was solubilized using solubilization agent (50 
µL/ well) and, after overnight incubation at 37 °C in the dark, the absorbance was read using 
the VarioSkan Flash plate reader (Thermo Fisher Scientific Inc) at 572 nm. The half-maximal 
inhibitory concentration (IC50) was determined as the drug concentration that resulted in a 50% 
reduction in cell viability. The results were expressed as a percentage relative to the control. 




Figure 10. Scheme of conversion of MTT to formazan salt by viable cells.  
 
 
2.5.3. DOX subcellular distribution (Fluorescence imaging) 
 
To observe the drug substance distribution in C-26 cells the confocal fluorescence imaging 
was used. The C-26 cells were seeded in a 6-well plate at a density of 65,000 cells per well in 
1 mL of DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin and 
incubated for 24 h at 37 °C in a humidified 5% CO2 atmosphere to allow cells to attach. 
Afterward, the medium was replaced by free DOX solution of PEG-PIONs/DOX in the culture 
medium at a concentration of 25 μM of DOX. After 24 h at 37 °C/5% CO2, cells were washed 
thrice with PBS and fixed with ethanol for 5 min. Subsequently, 4 μg/mL of Hoechst solution 
was added for 30 min to stain the nuclei. Finally, cells were washed thrice with PBS (pH 7.5), 
covered with PBS, and directly observed under a confocal laser scanning microscope (CLSM). 
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The CLSM images were obtained using a Zeiss Laser Scanning microscope LSM 700 (Carl 
Zeiss, Inc., USA) at excitation/emission filter wavelengths of 488 nm/505-605 nm for DOX 
and 405 nm/430-470 nm for Hoechst 33258. 
 
2.6. In vivo studies 
 
2.6.1. Biodistribution of PEG-PIONs/DOX 
 
All procedures involving animal care were approved by the Animal Ethics Committee 
of the University of Tsukuba and were conducted according to the Guidelines for Animal 
Experimentation of the University of Tsukuba. The in vivo distribution of the drug substance 
from PEG-PIONs/DOX or free DOX solution was examined in tumor-bearing male BALB/c 
mice (5-6-week-old; 20-24 g, n = 3-4 for each group). Tumors were induced in the mice by 
subcutaneous injection of C-26 cells into the right femur (1.0 × 106 cells/mouse) [Sumitani et 
al.2012]. When the tumor reached 100 mm3, BALB/c mice were administered intravenously 
with various DOX formulations, including: PEG-PIONs/DOX dispersion and free DOX 
solution, or saline (as a control group) via the tail vein at a single dose of DOX 10 or 20 mg/kg 
(10-12 mg Fe kg-1) [Chertok et al.2008]. Tumor volume was calculated using the following 
formula: (L×W2)/2, where L is the longest, and W is the shortest tumor diameter (mm), as 
measured by a caliper. At different time points i.e. 24 and 36 h post-injection blood samples 
were collected in a heparinized tubes by intracardiac puncture and then the major organs were 
harvested from the mice under sodium pentobarbital (40 mg/kg) anesthesia. The samples were 
frozen and stored at -80 °C until the further use. A simplified, rapid extraction procedure 
method was designed and appropriately modified to identify and quantify DOX in tissue 
extracts. To extract the drug from the organs, tissue samples were further optimized and 
processed to measure DOX content by using Liquid Chromatography – Mass Specroscopy (LC-
MS; LC Elite La Chrome Hitachi UV Detector L-2400U; MS AB Sciex API 2000 LC/MS/MS 
system, Tokyo, Japan) as follows. For analysis, frozen tissue samples (liver, heart, spleen and 
tumor) were removed from the freezer, and a 50-100 mg sample was quickly cut and transferred 
into a fresh, tared tube. A sufficient volume of mobile phase was added to achieve a final 
concentration of 12.5 – 25 % (w/v) tissue to solvent. The tissue homogenates were prepared 
using an ultra-sonic homogenizer (UH-50; SMT Company, Tokyo, Japan). All samples were 
homogenized briefly on ice (2 minutes), incubated on ice for 10 minutes and centrifuged for 13 
minutes at approximately 15,000 x g at 4ºC. The supernatant was recovered and analyzed 
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immediately. The composition of the mobile phase was optimized empirically to maximize 
sensitivity and minimize analytical time. The optimum extraction solvent consisted of 70% of 
acetonitrile, 30% of deionized water and 5% of acetic acid. Standard and quality control 
samples were prepared by extracting tissues obtained from untreated mice (from control group). 
 
2.6.2. Serum toxicity analysis 
 
At 24 h after the injection of PEG-PIONs/DOX dispersion, free DOX solution, or saline (as 
a control group) dosage, after the mice were anesthetized, blood samples were collected by 
intracardiac puncture using a heparinized syringe. Afterward, the blood was separated by 
centrifugation (6,200 rpm, 2000 g, for 10 min) and plasma was isolated for the analysis. Serum 
chemistry studies included evaluation of levels of aspartate aminotransferase (AST), blood urea 
nitrogen (BUN) (hepatic and renal function panels, respectively), and markers of cardiotoxicity 
such as creatine kinase (CK) and lactate dehydrogenase (LDH) were measured by a Fuji Dri-




All values are expressed along with respective means ± standard deviation (SEM). All 
values are expressed as SEM. Differences between groups were compared using one-way 
analysis of variance. All ANOVA were performed with ANOVA tests followed by Tukey’s 



















3. Results and discussion 
 
3.1. Characterization of Poly(ethylene glycol)-block-poly(4-
vinylbenzylphosphonate) block copolymer  
 
PEG-b-PVBP  was  synthesized  by  the  two-step  side-chain  conversion  of  the  PEG-
poly  (4-chloromethylstyrene) block copolymer (PEG-b-PCMS). The polymerization degree of 
PCMS segment (n) was determined as n = 14 by 1HNMR analysis (Figure 11), assuming the 
number-averaged molecular weight (Mn) of the PEG segment to be 5000 g mol
-1. The  
quantitative conversion of the chloromethyl side chains into phosphoric acid  groups was 
confirmed by  both  1H-  and  31P-NMR spectroscopy (Figure 11, Figure 12). The number-
averaged  molecular  weight  (Mn )  of  the  PEG  segment  was  5000  g  mol
-1, and  the  degree  











Figure 11. 1H-NMR spectra of PEG-b-PCMS, PEG-b-PDEVBP (400 MHz, acetone-d6, room 






Figure 12. 31P-NMR spectra of PEG-b-PDEVBP and PEG-b-PVBP (600 MHz,  methanol-d4, 
room temperature). 
 
3.2. Physicochemical characterization of PEG-PIONs/DOX 
 
A number of different methodologies have been reported to synthesize SPIONs, 
however commonly used co-precipitation method of iron salts under alkali conditions seems to 
be one of the best choices, due to its ease of operation and amenable scale-up. One of the major 
challenges related to SPIONs preparation is their surface modification, in order to avoid NPs 
aggregation. The coating procedure, and synthesis of NPs itself, used in my study has been 
optimized to prevent such aggregation and subsequently, the PEG-PIONs/DOX could be easily 
dispersed in appropriate medium and remain stable even at high ionic strength. PEG-
PIONs/DOX were prepared by the alkali co-precipitation of iron salts in the presence of PEG-
b-PVBP block copolymer. Synthesis of iron oxides NPs in a liquid phase containing stabilizer 
has been proved to be useful for controlling the particle size and preventing from their 
aggregation [Lutz et al.2006; Ishii et al.2004; Gu et al.2008; Papaphilippou et al.2009]. 
Aqueous dispersion of iron salts containing PEG-b-PVBP was prepared and NH4OH solution 
was then added to the mixture. The color of the solution changed immediately from yellow to 
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black after the addition of ammonia solution, indicating the generation of iron oxide NPs. In 
my study, DOX, an anthracycline antibiotic, was used as a model drug. DOX is one of the most 
widely used chemotherapeutic anticancer agents with a broad spectrum and high antitumor 
activity. It is usually used in the treatment of leukemia and various solid tumors and it has 
significant activity against tumor of the ovaries, lung, testis, prostate and bladder [Li et al.2011]. 
DOX inhibits DNA and proteins synthesis, and different mechanisms of action have been 
proposed to explain its’ effect. It exerts antitumor activity through inhibition of topoisomerase 
II, and therefore prevents chain unfolding and separation in DNA replication; in addition, it 
forms complexes with DNA by intercalation between base pairs and subsequent inhibition of 
DNA synthesis [Burden and Osheroff 1998; Sartiano, Lynch, and Bullington 1979]. However, 
systemic administration of DOX itself demonstrates severe side effects, including dose-
dependent cardiac toxicity and congestive heart failure, due to the lack of ability to target cancer 
cells [Chang et al.2011] and limits its clinical application. DOX is the drug model used in 
numerous published studies on delivery nanosystems. It possess the central anthracycline 
group, responsible for the intrinsic fluorescence of its molecule [Gautier et al.2013] (Figure 
13). Thus, its biodistribution in cells can be visualized using fluorescence-based microscopy 
and imaging. Modifying its biodistribution and clearance by using SPIONs as a carrier can more 
effectively  target them to tumor tissues, thus prevent the adverse effects and increase the 
efficacy of the drug [Munnier et al.2008; Aljarrah et al.2012].  
After the PEG-PIONs synthesis, DOX was loaded onto their surface using the adsorption 
technique. The pKa of DOX is 8.6, which provides positive charge to the drug in the neutral 
pH [(Gaihre et al.2009)] (pH of PEG-PIONs/DOX synthesis). The pKa value of PEG-b-PVBP 
is both 2.1 and 7.2; thus, at neutral conditions, about 25% of phosphonate groups are protonated, 
which imparts a negative charge to the polymer. Hence, the electrostatic interaction between 
the polymer and DOX and hydrophobic interaction between fused rings of DOX and the 
aromatic group of styrene from PEG-b-PVBP and IONs is the basis for the drug binding. Drug 
loading efficacy plays an important role in formulation of the drug delivery system and affects 
its therapeutic effect. The DOX encapsulation efficiency (EE) and DOX loading capacity (LC) 
into PEG-PIONs/DOX were estimated using UV-Vis spectroscopy. The results showed high 
efficacy of DOX loading, EE was 96.3% ± 0.8 and LC was 11.7% ± 0.5, which indicated 
relatively high efficiency of drug loading compared to that reported previously [Nigam, Barick, 
and Bahadur 2011; Rahimi et al.2010]. This high drug loading efficiency is critical to minimize 






Figure 13. Doxorubicin structure. 
 
 
The physicochemical properties of nanostructures designed for biomedical applications 
are the crucial parameters describing their quality [Hałupka-Bryl et al. 2015]. Therefore number 
of them like, the core size, morphology, hydrodynamic diameter and ζ-potential after synthesis, 
stability in different media, crystalline structure, complex formation between DOX and NPs as 
well as magnetic properties of these particles were evaluated using different methods.  
The core size of PEG-PIONs/DOX was visually confirmed by HRTEM measurements. Figure 
14 shows a typical HRTEM image of PEG-PIONs/DOX. The number-averaged diameters of 
the PEG-PIONs/DOX were determined by HRTEM image analyses. The images demonstrated 
a nearly spherical iron oxide core shape and uniform size distribution with the narrow range of 
8 – 12 nm. In the context of drug delivery, a narrow particle size range such as that obtained is 
useful since uniform size particles offer equal probability of magnetic capture of drug loaded 







Figure 14. HRTEM images of PEG-PIONs/DOX 
 
 
NPs designed for in vivo usage should be in the range of 10-100 nm to prevent elimination by 
the kidneys (<10 nm) and recognition by RES (>100 nm), therefore, PEG-PIONs/DOX are 
supposed to penetrate the tumor by the EPR effect, and neutral or slightly negative surface 
charge cause a reduced plasma protein adsorption and low rate of nonspecific cellular uptake.  
DLS was processed to determine a hydrodynamic size of synthesized NPs – these values are 
more significant than HRTEM data due to the fact that NPs will be used as a dispersions in 
appropriate medium and they provide information about actual size of whole core-shell 
nanosystem. The values of mean hydrodynamic diameter and ζ-potential of PEG-PIONs/DOX 
post-synthesis are in accordance with the statement above and are presented in Table 1. 
Prepared PEG-PIONs/DOX had particle size in the range of ~ 28 – 36 nm, and the electrokinetic 
potential was slightly negative, most likely resulting from the presence of numerous anionic 
phosphonate groups of PEG-b-PVBP polymer in the surface layer of the particles. A 
polydispersity index (PDI) describes the distribution in size measured by DLS. The value of 
PDI below 0.1 confirmed monodispersity of synthesized NPs.  
 
Table 1. Size and ζ-potential of synthesized PEG-PIONs/DOX 
Sample ≥ 10 Hydrodynamic 
diameter [nm] 
ζ-potential [mV] Polydispersity 
index (PDI) 





As it was mentioned before, dispersion stability of nanosized drug delivery systems plays 
crucial role in introducing them to in vivo biomedical applications. They should prevent 
aggregation and development of an embolism. PEG-PIONs/DOX showed excellent stability 
and good mono-dispersity in saline, PBS, and PBS containing 10% FBS over a period more 
than one month at room temperature (Figure 15). Phosphate salts from PBS are known to bind 
to the metal oxides surface and/or displace with the chemisorbed stabilizer, resulting in decrease 
in the dispersion stability [Goff et al.2009]. PEG-PIONs/DOX dispersed stably into PBS and 
showed no significant changes in their hydrodynamic diameter, which indicated that they are 
not prone to formation of aggregates under physiological conditions. The stability of the NPs 
in high ionic strength solution could be attributed to the steric repulsion, thus preventing the 
iron oxides cores from aggregating. It should be noted that the hydrodynamic diameter of PEG-
PIONs/DOX in saline and PBS was very similar to that in FBS. Therefore, good stability of 
PEG-PIONs/DOX was also confirmed in the serum-containing medium, which may suggest 
that synthesized NPs possess desired anti-biofouling surface properties, and this can be 
anticipated to increase their half-life in the bloodstream.  
 
  





The formation of a complex between PEG-PIONs and DOX was confirmed by size exclusion 
chromatography (SEC) on a PD-10 column (Figure 16). In the SEC method, compounds with 
a high molecular weight (PEG-PIONs/DOX) are excluded from Sephadex matrix and eluted 
first, while the compounds with a low molecular weight (free DOX) penetrate the pores to a 
varying extent and are eluted after large molecules. In our study, PEG- PIONs/DOX were eluted 
from 3-5 mL and elution of free DOX was observed from 7-16 mL. The results of UV-Vis 
measurements of obtained fractions indicated the formation of a complex between PEG-PIONs 





Figure 16. Confirmation of complex formation.  
 
 
XRD was performed to confirm the crystalline properties of the PEG-PIONs/DOX and 
confirmed the presence of pure phase of magnetite. Representative powder XRD patterns of 
PEG-PIONs/DOX are presented in Figure 17. The presence of sharp and intense peaks 
confirmed the formation of highly crystalline nanoparticles. The obtained results showed 
characteristic diffraction peaks (2θ = 30.2°, 35.5°, 43.2°, 53.6°, 57.2° and 62.8°) similar to those 
of magnetite (Fe3O4) [Gaihre et al.2009; Nigam, Barick, and Bahadur 2011]. The peaks 
corresponding to reflection planes are indexed. There often appears small contribution of 
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maghemite NPs in magnetite nanosystem, and these peaks also may occur in XRD examination. 
However, the absence of (210) and (300) peaks in the obtained XRD pattern, can indicate that 




Figure 17. Crystalline structure of PEG-PIONs/DOX. 
 
 
Magnetic properties of NPs depend on various factors such as their composition, size, thickness 
and type of surface coating. In order to study these crucial properties of prepared NPs we used 
SQUID. The hysteresis loop presented in Figure 18 demonstrates the magnetic behavior of 
PEG-PIONs/DOX. It shows the room temperature magnetization curve of PEG-PIONs/DOX 
where the magnetization curve demonstrates superparamagnetic behavior of these particles due 
to zero coercivity [Ling et al.2011]. Usually, particles exhibit such properties when the core 
size is sufficiently small (around 15 nm) [A. K. Gupta and Gupta 2005]. The small size is useful 
in drug delivery, as they do not retain magnetization before and after exposure to an external 
magnetic field, reducing the probability of particle aggregation in the smallest capillaries due 
to their magnetic dipole attraction. PEG-PIONs/DOX exhibited relatively high saturation 
magnetization values at high fields (around 30 emu/g at 40 kOe), where they approach to the 
saturation value and comparable to those previously reported [Maver et al.2009; Kayal and 





Figure 18. Magnetic properties of PEG-PIONs/DOX 
 
 
The other very useful, simple and accurate method to examine magnetic properties of SPIONs 
is EPR technique. The EPR spectra of PEG-PIONs and PEG-PIONs/DOX recorded at different 
temperatures and angles are shown in Figures 19 – 26. Typical EPR spectrum of these NPs is 
represented by a broad line assigned to the magnetite. As the temperature decreased the 
linewidth become broadened and its position shifted towards lower magnetic fields. This 







Figure 19. EPR spectra of PEG-PIONs/DOX recorded at 130 K and at 0º angle. 
 




Figure 21. EPR spectra of PEG-PIONs/DOX recorded at 250 K and at 0º angle. 
 




Figure 23. EPR spectra of PEG-PIONs recorded at 130 K and at 0º angle. 
 




Figure 25. EPR spectra of PEG-PIONs recorded at 250 K and at 0º angle. 
 




Characteristic spectroscopic parameters such as resonance field (Hr), g-factor value and peak-
to-peak line width (ΔH) were determined for the EPR spectra recorded at different 
temperatures, under both 0º and 90º angles. The measurement uncertainty were respectively ± 
1.2 mT for Hr, ± 0.003 for g-factor and ± 0.6 mT for ΔH. Figures 27 - 29 shows the temperature 
and angular changes of those parameters. With increasing temperature the wide line was shifted 
towards higher values of the resonance field (Hr) (Fig. 27). The opposite temperature 
dependence was observed for g-factor (Fig. 28). The peak-to-peak line width (ΔH) decreased 
with increasing temperature (Fig. 29), which is typical for superparamagnetic NPs [Berger 
Bissey, Kliava, and Estourn 2001]. The particular difference between PEG-PIONs and PEG-
PIONs/DOX sample for angle 0º was observed (Table 2). Smaller changes of resonance field 
for PEG-PIONs than for PEG-PIONs/DOX were caused by the rotation of the sample at an 
angle of 0º and it testified that DOX incorporation onto NPs surface causes easier ordering of 
the sample in the external magnetic field. Higher value of g-factor for PEG-PIONs/DOX in 
comparison to PEG-PIONs indicates increased anisotropic field and higher effective anisotropy 
field coefficient for PEG-PIONs/DOX [Figueiredo et al.2008]. Similarly, there is higher 
difference in Hr values for 0º and 90º for PEG-PIONs/DOX than PEG-PIONs [Fig. 26, Table 
2] which testifies increased anisotropic field and higher effective anisotropy field coefficient 
for PEG-PIONs/DOX. Taking into consideration the above results, and the fact that 
concentration and size distribution of NPs in both samples are very similar, it can be  
hypothesized that the alterations in EPR parameters may be due to some minor changes in the 
subsurface area of NPs (e.g. slight oxidation process in subsurface area of PEG-PIONs, which 
are not additionally stabilized by DOX molecules).  
 
Table 2. The EPR data for PEG-PIONs vs. PEG-PIONs/DOX recorded at  250 K at 0º and  90º 
angle.  










Hr [mT] 321.3 331.5 326.4 330.2 






Figure 27. Changes of resonance field (Hr) versus angle and temperature for PEG-PIONs and 
PEG-PIONs/DOX. 
 





Figure 29. Changes of peak-to-peak line width (ΔH) versus angle and temperature for PEG-
PIONs and PEG-PIONs/DOX. 
 
From the line shape analysis it was possible to determine the magnetocrystalline anisotropic 
constant of first order K1, following a method described in the literature [Gamarra et al. 2009]. 
This value is related to structure and size of NPs, and their modifications including 
functionalization can influence its value. K1 was determined by using the relations                           
K1 = Ha x MS / 2, where Ha = 3/5ΔH. MS is the saturation magnetization of PEG-PIONs/DOX 
at 40kOe (~ 30 emu/g) obtained from SQUID studies and the Ha value was obtained from the 
field separation between the wing positions of Hmax and Hmin, as shown in figures 30 - 33. For 
K1 of PEG-PIONs calculation, MS for PEG-PIONs/DOX was taken. The K1 value for PEG-
PIONs/DOX at 140K was K1 = 9.5 x 10
3 erg cm−3 and at room temperature was K1 = 7.1 x 10
3 
erg cm−3. The K1 value for PEG-PIONs at 140K was K1 = 8.7 x 10
3 erg cm−3 and at room 
temperature was K1 = 6.3 x 10
3 erg cm−3. The determined magnetocrystalline anisotropic 
constant increased with decrease of temperature and was higher for PEG-PIONs/DOX, which 












Figure 32. EPR spectrum of PEG-PIONs at 140K. 
 
Figure 33. EPR spectrum of PEG-PIONs at room temperature. 
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3.3. In vitro studies 
 
3.3.1. DOX release profile 
 
NPs designed for in vivo applications are coated by different surface agents such as e.g. 
polymers, which release the drug molecules by controlled diffusion or erosion from the core 
surface across the polymeric membrane or matrix. The membrane coating acts as a barrier to 
release, thus the diffusivity and solubility of the active substance in polymer coating becomes 
crucial in drug release. Release profile can be also affected by ionic interaction between the 
drug and additional ingredients. When drug interacts with some auxiliary molecules to form a 
less soluble complex in water, then its drug release profile can be very slow without burst effect 
[Y. Chen, Mcculloch, and Gray 1994]. It was reported previously that pH of tumor 
microenvironment is shifted to acidic region [Kievit et al.2011; Yang et al.2011]. PEG-
PIONs/DOX were incubated at different pH media to examine drug release under conditions 
likely encountered following NPs tumor uptake and intracellular sequestration. The pH levels 
chosen replicated that found in the blood (pH 7.4), as well as the acidity characteristic of the 
tumor microenvironment (pH 5.7). DOX release behavior was examined in dark at a 
temperature of 37 °C to mimic the conditions of body fluids. It was assumed that DOX release 
would be faster at mildly acidic pH values than at neutral pH as a consequence of weakened 
binding between drug substance and the partially neutralized phosphonate groups in block 
copolymer coating. At both pH conditions, no burst effect was observed. As expected, the 
release rate of DOX (Figure 34) was higher at pH 5.7 than at pH 7.4 (approximately 20% and 
10%, respectively). The shape of the release profile indicated that the complete release of the 
drug reached plateau only at neutral condition and DOX molecules were released slowly over 
a period of 96 h at lower pH. It can be noted that free DOX solution (taken as a control) was 
immediately released from dialysis membrane at both pH. These data imply that the physically 
bound drug molecules could be faster and continuously released in the mild acidic environments 
than at physiologically neutral pH of blood in the vascular compartment. This phenomenon 
could be explained by the fact that at a lower pH, the release of drug molecules was controlled 
by diffusion of the DOX through the PEG-b-PVBP polymer. The release of the active substance 
could be attributed to the weakening of the electrostatic interactions between the drug and the 
partially neutralized phosphonate groups of the polymer, because at acidic conditions, ~45-55% 
of phosphonate groups of PVBP chains in the PEG-PIONs/DOX are protonated [Kamimura et 
al. 2012]. However, weakening of the electrostatic interactions is a slow process, which leads 
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to the continuous release of DOX over a period of 96 h. Slower release in the tumor site may 
continue the chemotherapeutic effect and therefore increase the efficacy of anticancer therapy. 
This accelerated release of DOX at pH 5.7 will be particularly of benefit to anticancer therapy 
because of more acidic environment in tumor tissues. NPs tend to accumulate in tumor region 
gradually via the EPR effect and achieve a maximum concentration after several hours. These 
results indicate that the DOX could be released in substantial amounts in the acidic tumor 
region. Slow DOX release rate from PEG-PIONs/DOX can reflect its better stability and strong 





Figure 34. DOX release profile from PEG-PIONs/DOX at pH 5.7 (solid square ) and pH 7.4 
(solid circle ) buffer solution at 37 °C.  
 
3.3.2. Cell culture and in vitro cytotoxicity assay 
 
The in vitro antiproliferative effect on cancer cells (C-26 cell line) of the PEG-
PIONs/DOX in comparison to free DOX solution was evaluated using the MTT assay. Cells 
were incubated in the presence of different drug formulations at DOX concentrations from 1 to 
50 μM for 24 h and 72 h. These doses for cytotoxic effect were confirmed on the basis of 
previous studies with DOX on cancer cell lines [S. Park et al.2012]. The cytotoxicity of PEG-
PIONs/DOX and free DOX solutions (taken at the same drug concentration) was compared. 
PEG-PIONs (at Fe concentration of typical ion-based drug delivery systems for mice (1-15 mg 
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Fe mL-1 )) showed minimal toxicity: cell viability was 98.1 % ± 1.3 and 97. 2 % ± 2.2 after 24 
h and 72 h, respectively. The antiproliferative profiles, i.e., the cell viability after treatment for 
24 and 72 h versus drug concentration are shown in Figure 35. Compared to free DOX solution, 
DOX-incorporated PEG-PIONs showed lower cytotoxicity. The IC50 values were determined 
to be 33.06 μM and 23.14 μM after 24 h and 25.3 μM and 14.1 μM after 72 h of incubation 
with PEG-PIONs/DOX and free DOX solution, respectively. It can be assumed that not all 
DOX was released from the PEG-PIONs/DOX because of electrostatic and hydrophobic 
interactions. Similar to that reported previously [Shkilnyy et al.2010; Gautier et al.2012; Yang 
et al.2011], the results of cytotoxicity assay showed that the cell viability decreased with an 
increase in the concentration of DOX nano-formulation. Nevertheless, DOX incorporated into 
PEG-PIONs surface showed lower toxicity against C-26 cancer cells than free DOX solution, 
which may suggest high stability of the PEG-PIONs/DOX complex even in cell cultivation 





Figure 35. Cell viability of C-26 cells incubated with various concentrations of PEG-
PIONs/DOX (solid circle ) and free DOX (solid square ) measured by MTT assay after 24 







3.3.3. DOX subcellular distribution (Fluorescence imaging) 
 
The magnetic NPs can be targeted to tumor tissue by the EPR effect, appropriate surface 
modification (targeting ligands attached) and external magnetic field. The internalization ability 
of magnetic nanocarriers into cancer cells is a crucial factor to reach optimal curative effect of 
drug, due to the fact that DOX exerts its effect in the nucleus [Ying et al.2011]. If the drug is 
covalently attached to NPs it could need specific enzymes in lysosomes to trigger its release 
and the whole particle has to enter the cell. However, in the case of physical interaction, simple 
diffusion through the polymer can be sufficient to desorb drug from the particle [Douziech-
Eyrolles et al.2007]. The cellular uptake ability of synthesized NPs was examined using CLSM. 
In this study, the fluorescence signal from PEG-PIONs/DOX allowed us to follow the 
intracellular DOX release in C-26 cell line used as a model tumor cell. As anticipated, after 24 
h of incubation (Figure 36) with free DOX, the drug was primarily present in the nucleus and 
in the cytoplasm, with small regions of punctuated accumulation in cellular compartments. In 
contrast, after 24 h of incubation with DOX conjugated to PEG-PIONs/DOX, the active 
substance was mainly localized in subcellular vesicles or organelles within the cytoplasm and 
only small amounts were present in the nucleus. However, after 72 h (Figure 37) of incubation 
with PEG-PIONs/DOX dispersion, the amount of released DOX very slightly increased, which 
is consistent with the drug release profile, but the drug molecules shifted into the nucleus in 
significant amount, where DOX can exhibit its mechanism of action. These results may indicate 
that free and conjugated DOX use different uptake mechanisms, suggesting that the conjugated 
DOX was taken up by endocytosis [Laurent et al. 2008; Singh et al. 2010]. The above results 
may also indicate that the active substance is released from PEG-PIONs/DOX in the endocytic 






Figure 36. Fluorescent images of cells incubated with 25 μM DOX formulations (free cells as 
a control) for 24 h (a, b, c -  PEG- PIONs/DOX; d, e, f - free DOX solution, g, h, i – cells in 







Figure 37. Fluorescent images of cells incubated with 25 μM DOX formulations (free cells as 
a control) for 72 h (a, b, c -  PEG- PIONs/DOX; d, e, f - free DOX solution, g, h, i – cells in 
PBS). Nuclei are stained in Hoechst solution (blue), red is DOX distribution.  
 
3.4. In vivo studies 
 
The biodistribution of drug substance from nanocarrier was evaluated in animal mice 
model in comparison with free drug solution. Free DOX solution and PEG-PIONs/DOX 
dispersion at the equivalent DOX dose of 10 or 20 mg/kg body weight, as well as saline as a 
control group were intravenously administered to tumor-bearing BALB/c mice. The major 
organs were collected and extracted for the DOX measurements after 24 h and 36 h. A 
simplified rapid extraction procedure was developed and optimized to identify and quantify 
DOX levels in the tissue extracts using LC-MS method. Compared to the free drug, PEG-
PIONs/DOX significantly increased drug accumulation into the tumor region (Figure 38). The 
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preferential uptake of DOX formulation is likely due to the prolonged circulation and EPR 
effect [Rosen et al.2012; Hiroshi Maeda 2001]. Drug delivery nanocarriers increase the 
intratumoral drug concentration mainly because of their nanometer size. The leaky fenestrations 
of the neovasculature system in the tumor damaged tumor vasculature,  poorly developed and 
inefficient lymphatic drainage enable extravasation and accumulation of such small objects. 
This results in accumulation of NPs for a prolonged period of time. Our biodistribution studies 
showed preferential accumulation of PEG-PIONs/DOX in the tumor tissue. Furthermore, it was 
noted that DOX nanoparticulate formulation reduced significant amounts of drug distribution 
into the heart compared with free DOX solution, which may lower DOX-associated 
cardiotoxicity. In addition, the toxicity in all mice was monitored by serum chemistry 
examinations (Figure 39, 40), including hepatic and renal panels as well as cardiac enzymes 
(AST, BUN, LDH, and CK). The hepatic and renal function tests indicated that AST and BUN 
levels did not change significantly in all groups compared to those in the control group. Serum 
CK and LDH levels are two well-characterized markers for cellular damage in a variety of 
cardiac disease models. Importantly, encapsulation of DOX onto PEG-PIONs/DOX nanocarrier 
was found to decrease the cardiotoxicity compared with free drug. The induction of CK and 
LDH enzymes in the serum of mice treated with free DOX solution was significantly increased, 
compared with untreated mice. However, when mice were treated with PEG-PIONs/DOX, both 
serum CK and LDH levels were not significantly different from saline control group. The 
decreased cardiotoxicity of PEG-PIONs/DOX formulations can be attributed to the reduced 
uptake in the heart as demonstrated in the above in vivo biodistribution studies. These results 
may indicate that PEG-PIONs/DOX have the potential for their application in targeted delivery 








Figure 38. The biodistribution data of PEG-PIONs/DOX  (PPD) and free DOX solution (DOX) 
at the dose of 10 and 20 mg/kg mice after 24 h (a) and 36 h (b) of intravenous injection compared 
to saline (control group). Values are expressed as ± SEM. * P < 0.05 as compared PEG-





























































































































































































































































































































































The main objective of this work was to design a stable, biocompatible and injectable 
nanocarrier with antiproliferative effect on cancer cells and high drug encapsulation efficiency. 
The synthesis, functionalization of prepared nanosystem and detailed characterization of PEG-
PIONs/DOX enabled to prove the usefulness of the nanocarrier as a potential targeted drug 
delivery system. Hereafter, several most important conclusions are highlighted. 
 
1. PEG-PIONs/DOX were successfully synthesized by appropriately optimized alkali co-
precipitation method with original polymer PEG-derivative and the anticancer agent. 
Several techniques were used to test the quality of as-synthesized NPs. 
 
2. PEG-PIONs/DOX showed nearly  spherical  shape  and  uniform  size  distribution with 
the narrow range of 8 – 12 nm.  
 
3. Synthesized NPs showed very high efficacy of DOX loading, relatively higher 
compared to that previously reported.  
 
4. The magnetic properties of obtained material was tested by several methods. SQUID 
magnetization curve demonstrated superparamagnetic behavior of PEG-PIONs/DOX. 
The presence of sharp and intense peaks obtained by XRD studies confirmed the 
formation of highly crystalline Fe3O4 NPs.  
 
5. The EPR temperature measurements demonstrated the superparamagnetic nature of 
PEG-PIONs/DOX and magnetite structure of their cores. The alterations in 
magnetocrystalline anisotropic coefficient (K1) may indicate the surface changes of 
synthesized PEG-PIONs/DOX related to their functionalization and modification. The 
higher value of K1 indicates that the lower thickness of canted surface spins in the case 
of PEG-PIONs/DOX. 
 
6. Prepared nanocarriers demonstrated excellent stability in dispersions mimicking 




7. The studies using size exclusion chromatography confirmed the formation of a complex 
between PEG-PIONs and DOX.  
 
8. The in vitro studies of DOX release rate showed sustained and continuous drug release, 
which was higher at pH 5.7 than at pH 7.4. This accelerated release of DOX at pH 5.7 
would be particularly of benefit to anticancer therapy because of more acidic 
environment in tumor tissues.  
 
9. Fluorescence imaging studies showed that PEG-PIONs/DOX have been successfully 
used for the efficient delivery of an anticancer drug into the tumor region.  
 
10. The in vitro cytotoxicity studies demonstrated the antiproliferative effect of PEG-
PIONs/DOX on cancer cells, as a result of slowly released drug from synthesized 
nanosystem. DOX incorporated into PEG-PIONs showed lower toxicity against cancer 
cells than free DOX solution. 
 
11. The performed in vivo biodistribution studies showed that the uptake of PEG-
PIONs/DOX in the tumor tissue was greater than that of an equivalent dose of DOX in 
BALB/c tumor-bearing mice. The serum chemistry examinations were also monitored 
and proved that the DOX-associated cardiotoxicity was significantly reduced.  
 
Based on the obtained results, it can be concluded that PEG-PIONs/DOX are promising 
magnetic drug carriers to be used in biomedical applications. Taking into consideration that 
even without external magnetic field PEG-PIONs/DOX easily accumulate in tumor region, one 
may predict its high efficacy in future therapy, avoiding side effects of low-molecular weight 
anticancer drugs like DOX, which frequently causes severe cardiotoxicity. The developed 
material may be used in the future as a potential drug delivery system of anticancer agents in 
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